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t is essential that the medical profession play a central role
n critically evaluating the evidence related to drugs, devices,
nd procedures for the detection, management, or preven-
ion of disease. Properly applied, rigorous, expert analysis of
he available data documenting absolute and relative bene-
ts and risks of these therapies and procedures can improve
he effectiveness of care, optimize patient outcomes, and
avorably affect the cost of care by focusing resources on the
ost effective strategies. One important use of such data is
he production of clinical practice guidelines that, in turn,
an provide a foundation for a variety of other applications,
uch as performance measures, appropriate use criteria,
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The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of guidelines in the area of
ardiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines (Task Force) is charged with
eveloping, updating, and revising practice guidelines for
ardiovascular diseases and procedures, and the Task Force
irects and oversees this effort. Writing committees are
harged with assessing the evidence as an independent
roup of authors to develop, update, or revise recommen-
ations for clinical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines in partnership with representatives
rom other medical practitioner and specialty groups. Writ-
ng committees are specifically charged to perform a formal
iterature review; weigh the strength of evidence for or
gainst particular tests, treatments, or procedures; and
nclude estimates of expected health outcomes where data
xist. Patient-specific modifiers, comorbidities, and issues of
atient preference that may influence the choice of tests or
herapies are considered. When available, information from
tudies on cost is considered, but data on efficacy and clinical
utcomes constitute the primary basis for recommendations
n these guidelines.
In analyzing the data and developing recommendations
nd supporting text, the writing committee used evidence-
ased methodologies developed by the Task Force that are
escribed elsewhere (1). The committee reviewed and
anked evidence supporting current recommendations, with
he weight of evidence ranked as Level A if the data were
erived from multiple randomized clinical trials or meta-
nalyses. The committee ranked available evidence as Level
when data were derived from a single randomized trial or
onrandomized studies. Evidence was ranked as Level C
hen the primary source of the recommendation was
onsensus opinion, case studies, or standard of care. In the
arrative portions of these guidelines, evidence is generally
resented in chronological order of development. Studies
re identified as observational, retrospective, prospective, or
andomized when appropriate. For certain conditions for
hich inadequate data are available, recommendations are
ased on expert consensus and clinical experience and
anked as Level C. An example is the use of penicillin for
neumococcal pneumonia, where there are no randomized
rials and treatment is based on clinical experience. When
ecommendations at Level C are supported by historical
linical data, appropriate references (including clinical re-
iews) are cited if available. For issues where sparse data are
vailable, a survey of current practice among the clinicians
n the writing committee was the basis for Level C
ecommendations and no references are cited. The schema
or Classification of Recommendations (COR) and Level of
vidence (LOE) is summarized in Table 1, which also tllustrates how the grading system provides an estimate of
he size as well as the certainty of the treatment effect. A
ew addition to the ACCF/AHA methodology is a sepa-
ation of the Class III recommendations to delineate
hether the recommendation is determined to be of “no
enefit” or associated with “harm” to the patient. In addi-
ion, in view of the increasing number of comparative
ffectiveness studies, comparator verbs and suggested
hrases for writing recommendations for the comparative
ffectiveness of one treatment/strategy with respect to an-
ther for COR I and IIa, LOE A or B only, have been
dded.
The Task Force on Practice Guidelines makes every effort
o avoid actual, potential, or perceived conflicts of interest
hat may arise as a result of industry relationships or
ersonal interests among the writing committee. Specifi-
ally, all members of the writing committee, as well as peer
eviewers of the document, are asked to disclose ALL
elevant relationships and those existing 24 months before
nitiation of the writing effort. All guideline recommenda-
ions require a confidential vote by the writing committee
nd must be approved by a consensus of the members
oting. Members who were recused from voting are noted
n the title page of this document and in Appendix 1.
embers must recuse themselves from voting on any
ecommendation to which their relationship with industry
nd other entities (RWI) applies. Any writing committee
ember who develops a new RWI during his or her tenure
s required to notify guideline staff in writing. These
tatements are reviewed by the Task Force on Practice
uidelines and all members during each conference call and
eeting of the writing committee and are updated as
hanges occur. For detailed information about guideline
olicies and procedures, please refer to the ACCF/AHA
ethodology and policies manual (1). Authors’ and peer
eviewers’ RWI pertinent to this guideline are disclosed in
ppendixes 1 and 2, respectively. In addition, to ensure
omplete transparency, writing committee members’ com-
rehensive disclosure information—including RWI not perti-
ent to this document—is available online as a supplement
o this document. Disclosure information for the ACCF/
HA Task Force on Practice Guidelines is available online
t www.cardiosource.org/ACC/About-ACC/Leadership/
uidelines-and-Documents-Task-Forces.aspx. The work
f the writing committee was supported exclusively by the
CCF and AHA without commercial support. Writing
roup members volunteered their time for this effort.
The ACCF/AHA practice guidelines address patient
opulations (and health care providers) residing in North
merica. As such, drugs that are not currently available in
orth America are discussed in the text without a specific
lass of recommendation. For studies performed in large
umbers of subjects outside of North America, each writing
ommittee reviews the potential impact of different practice
atterns and patient populations on the treatment effect and
he relevance to the ACCF/AHA target population to
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ecommendation.
The ACCF/AHA practice guidelines are intended to
ssist healthcare providers in clinical decision making by
escribing a range of generally acceptable approaches to the
iagnosis, management, and prevention of specific diseases
r conditions. These practice guidelines represent a consen-
us of expert opinion after a thorough and systematic review
f the available current scientific evidence and are intended
o improve patient care. The guidelines attempt to define
ractices that meet the needs of most patients in most
ituations. The ultimate judgment regarding care of a
able 1. Applying Classification of Recommendations and Leve
■ 
Data available from clinical trials or registries about the usefulness/efficacy in different subpop
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may be
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and
reatments or strategies being evaluated.articular patient must be made by the healthcare provider rnd patient in light of all the circumstances presented by
hat patient. Thus, there are circumstances in which devi-
tions from these guidelines may be appropriate. Clinical
ecision making should consider the quality and availability
f expertise in the area where care is provided. When these
uidelines are used as the basis for regulatory or payer
ecisions, the goal should be improvement in quality of care.
he Task Force recognizes that situations arise in which
dditional data are needed to better inform patient care;
hese areas will be identified within each respective guide-
ine when appropriate.
Prescribed courses of treatment in accordance with these
vidence
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
clear clinical consensus that a particular test or therapy is useful or effective.
, studies that support the use of comparator verbs should involve direct comparisons of thel of E
ulations
at the r
a veryecommendations are effective only if they are followed.
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dversely affect outcomes, physicians and other healthcare
roviders should make every effort to engage the patient’s
ctive participation in prescribed medical regimens and
ifestyles.
The guidelines will be reviewed annually by the Task
orce and considered current until they are updated, revised,
r withdrawn from distribution. The executive summary
nd recommendations are published in the Journal of the
merican College of Cardiology, Circulation, and the Journal of
ardiovascular Computed Tomography.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, when-
ver possible, evidence based. An extensive evidence review
as conducted for the period beginning March 2008
hrough April 2010. Searches were limited to studies,
eviews, and other evidence conducted in human subjects
nd published in English. Key search words included, but
ere not limited to, African Americans, Asian Americans,
lbuminuria, asymptomatic, asymptomatic screening and bra-
hial artery reactivity, atherosclerosis imaging, atrial fibrilla-
ion, brachial artery testing for atherosclerosis, calibration,
ardiac tomography, compliance, carotid intima-media thickness
IMT), coronary calcium, coronary computed tomography an-
iography (CCTA), C-reactive protein (CRP), detection of
ubclinical atherosclerosis, discrimination, endothelial function,
amily history, flow-mediated dilation, genetics, genetic screen-
ng, guidelines, Hispanic Americans, hemoglobin A, glycosy-
ated, meta-analysis, Mexican Americans, myocardial perfusion
maging (MPI), noninvasive testing, noninvasive testing and
ype 2 diabetes, outcomes, patient compliance, peripheral arterial
onometry (PAT), peripheral tonometry and atherosclerosis,
ipoprotein-associated phospholipase A2, primary prevention of
oronary artery disease (CAD), proteinuria, cardiovascular risk,
isk scoring, receiver operating characteristics (ROC) curve,
creening for brachial artery reactivity, stress echocardiography,
ubclinical atherosclerosis, subclinical and Framingham, sub-
linical and Multi-Ethnic Study of Atherosclerosis (MESA),
nd type 2 diabetes. Additionally, the writing committee
eviewed documents related to the subject matter previously
ublished by the ACCF and AHA, American Diabetes
ssociation (ADA), European Society of Cardiology, and
he Joint National Committee on Prevention, Detection,
valuation, and Treatment of High Blood Pressure (JNC)
. References selected and published in this document are
epresentative and not all-inclusive.
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published in the
rticle, data from the clinical trial will be used to calculate
he absolute risk difference and number needed to treat or Sarm; data related to the relative treatment effects will also
e provided, such as odds ratio (OR), relative risk (RR),
azard ratio (HR), or incidence rate ratio (IRR), along with
onfidence interval (CI) when available.
The focus of this guideline is the initial assessment of the
pparently healthy adult for risk of developing cardiovascu-
ar events associated with atherosclerotic vascular disease.
he goal of this early assessment of cardiovascular risk in an
symptomatic individual is to provide the foundation for
argeted preventive efforts based on that individual’s pre-
icted risk. It is based on the long-standing concept of
argeting the intensity of drug treatment interventions to
he severity of the patient’s risk (2). This clinical approach
erves as a complement to the population approach to
revention of cardiovascular disease (CVD), in which
opulation-wide strategies are used regardless of an individ-
al’s risk.
This guideline pertains to initial assessment of cardiovas-
ular risk in the asymptomatic adult. Although there is no
lear age cut point for defining the onset of risk for CVD,
levated risk factor levels and subclinical abnormalities can
e detected in adolescents as well as young adults. To
aximize the benefits of prevention-oriented interventions,
specially those involving lifestyle changes, the writing
ommittee advises that these guidelines be applied in
symptomatic persons beginning at age 20. The writing
ommittee recognizes that the decision about a starting
oint is an arbitrary one.
This document specifically excludes from consideration
atients with a diagnosis of CVD or a coronary event, for
xample, angina or anginal equivalent, myocardial infarction
MI), or revascularization with percutaneous coronary in-
ervention or coronary artery bypass graft surgery. It also
xcludes testing for patients with known peripheral artery
isease (PAD) and cerebral vascular disease. This guideline
s not intended to replace other sources of information on
ardiovascular risk assessment in specific disease groups or
igher-risk groups such as those with known hypertension
r diabetes who are receiving treatment.
.2. Organization of the Writing Committee
he committee was composed of physicians and others
xpert in the field of cardiology. The committee included
epresentatives from the American Society of Echocardiog-
aphy (ASE), American Society of Nuclear Cardiology
ASNC), Society of Atherosclerosis Imaging and Preven-
ion (SAIP), Society for Cardiovascular Angiography and
nterventions (SCAI), Society of Cardiovascular Computed
omography (SCCT), and Society for Cardiovascular
agnetic Resonance (SCMR).
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers nomi-
ated by the ACCF and 2 outside reviewers nominated by
he AHA, as well as 2 reviewers each from ASE, ASNC,
AIP, SCAI, SCCT, and SCMR, and 23 individual con-
t
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se Criteria Task Force, ACCF Cardiac Catheterization
ommittee, ACCF Imaging Council, and ACCF Preven-
ion of Cardiovascular Disease Committee). All reviewer
WI information was collected and distributed to the
riting committee and is published in this document
Appendix 2).
This document was approved for publication by the
overning bodies of the ACCF and AHA and endorsed by
SE, ASNC, SAIP, SCCT, and SCMR.
.4. Magnitude of the Problem of Cardiovascular
isk in Asymptomatic Adults
therosclerotic CVD is the leading cause of death for both
en and women in the United States (3). Risk factors for
he development of atherosclerotic disease are widespread in
he U.S. population. In 2003, approximately 37% of Amer-
can adults reported having2 risk factors for CVD. Ninety
ercent of patients with coronary heart disease (CHD) have
t least 1 atherosclerotic risk factor (4). Approximately half
f all coronary deaths are not preceded by cardiac symptoms
r diagnoses (5). One aim of this guideline is to provide an
vidence-based approach to risk assessment in an effort to
ower this high burden of coronary deaths in asymptomatic
dults.
CVD was mentioned on the death certificates of 56% of
ecedents in 2005. It was listed as the underlying cause of
eath in 35.3% (864,480) of all deaths (2,448,017) in 2005
r 1 of every 2.8 deaths in the U.S. (6). In every year since
900 (except 1918), CVD accounted for more deaths than
ny other major cause of death in the United States (6). It
s estimated that if all forms of major CVD were eliminated,
ife expectancy would rise by almost 7 years (6). Analyses
uggest that the decrease in U.S. deaths due to CHD from
980 to 2000 was partly attributable (approximately 47%) to
vidence-based medical therapies, and about 44% of the
eduction has been attributed to changes in risk factors in
he population (7). The estimated direct and indirect cost of
VD for 2009 is $475.3 billion (6).
CHD has a long asymptomatic latent period, which
rovides an opportunity for early preventive interventions.
therosclerosis begins in childhood and progresses into
dulthood due to multiple coronary risk factors such as
nfavorable levels of blood lipids, blood pressure, body
eight and body fat, smoking, diabetes, and genetic predis-
osition (8–10). The lifetime risk of CHD and its various
anifestations has been calculated for the Framingham
eart Study population at different ages. In nearly 8000
ersons initially free of clinical evidence of CHD, the
ifetime risk of developing clinically manifest CHD (angina
ectoris, MI, coronary insufficiency, or death from CHD) at
ge 40 was 48.6% for men and 31.7% for women (11). At
ge 70, the lifetime risk of developing CHD was 34.9% for
en and 24.2% for women. The lifetime risk for all CVDombined is nearly 2 of every 3 Americans (12). Thus, the 1roblem is immense, but the preventive opportunity is also
reat.
.5. Assessing the Prognostic Value of Risk
actors and Risk Markers
any risk factors have been proposed as predictors of CHD
13,14). New risk factors or markers are frequently identi-
ed and evaluated as potential additions to standard risk
ssessment strategies. The AHA has published a scientific
tatement on appropriate methods for evaluating the pre-
ictive value of new risk factors or risk markers (15). The
cientific statement endorsed previously published guide-
ines for proper reporting of observational studies in epide-
iology (16) but also went beyond those guidelines to
pecifically address criteria for evaluation of established and
ew risk markers. The current writing committee endorses
his scientific statement and incorporated these principles
nto the assessments for this guideline. The general concepts
nd requirements for new risk marker validation and eval-
ation are briefly reviewed to provide a basis for the
ssessments in this document.
For any new risk marker to be considered useful for risk
rediction, it must, at the very least, have an independent
tatistical association with risk after accounting for estab-
ished readily available and inexpensive risk markers. This
ndependent statistical association should be based on stud-
es that include large numbers of outcome events. Tradi-
ionally, reports of novel risk markers have only gone this
ar, reporting adjusted HRs with CIs and p values (17).
lthough this level of basic statistical association is often
egarded by researchers as meaningful in prediction of a
articular outcome of interest, the AHA scientific statement
alled for considerably more rigorous assessments that
nclude analysis of the calibration, discrimination, and
eclassification of the predictive model. Many of the tests
eviewed in this guideline fail to provide these more com-
rehensive measures of test evaluation, and for this reason,
any tests that are statistically associated with clinical
utcomes cannot be judged to be useful beyond a standard
isk assessment profile. In the absence of this evidence of
additive predictive information,” the writing committee
enerally concluded that a new risk marker was not ready for
outine use in risk assessment.
Calibration and discrimination are 2 separate concepts
hat do not necessarily track with each other. Calibration
efers to the ability to correctly predict the proportion of
ubjects within any given group who will experience disease
vents. Among patients predicted to be at higher risk, there
ill be a higher number of events, whereas among patients
dentified as being at lower risk, there will be fewer events.
or example, if a diagnostic test or a multivariable model
plits patients into 3 groups with predicted risks of 5%, 10%,
nd 15% within each group, calibration would be considered
ood if in a separate group of cohorts with similar predicted
isks, the actual rates of events were close to 5%, 10%, and
5%. Calibration is best presented by displaying observed
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or models that do and do not include the new risk marker.
Discrimination is a different concept that refers to the
robability of a diagnostic test or a risk prediction instru-
ent to distinguish between patients who are at higher
ompared with lower risk. For example, a clinician sees 2
andom patients, 1 of whom is ultimately destined to
xperience a clinical event. A diagnostic test or risk model
iscriminates well if it usually correctly predicts which of the
subjects is at higher risk for an event. Mathematically this
s described by calculating a C index or C statistic, param-
ters that are analogous to the area under the ROC curve.
hese statistics define the probability that a randomly
elected person from the “affected group” will have a higher
est score than a randomly selected person from the “non-
ffected group.” A test with no discrimination would have a
statistic of 0.50 and a perfect test would have a C statistic
f 1.0. Throughout this document, C statistic information is
ited where available.
As an example of a risk marker that improves discrimi-
ation, MESA investigators found that the addition of
oronary artery calcium (CAC) scores to standard risk
actors improved the area under the ROC curve from 0.77
o 0.82 (p0.001) (18). In contrast, a score based on 9 genes
hat code for cholesterol levels added no predictive value
ver established risk factors and family history (19). Simi-
arly, a study comparing the predictive capacity of conven-
ional and newer biomarkers for prediction of cardiovascular
vents derived a C statistic of 0.760 for coronary events for
he conventional risk factor model. Adding a number of
ewer biomarkers changed the C statistic by only 0.009
p0.08) (20). Small changes such as these in the C statistic
uggest limited or rather modest improvement in risk
iscrimination with additional risk markers.
Some investigators have called for evaluating the num-
er of subjects reclassified into other risk categories based
n models that include the new risk marker (21). For
xample, in a model of cardiovascular risk in a large
ohort of healthy women, the addition of CRP resulted
n reclassification of a large proportion of subjects who
ere thought to be at intermediate risk based on standard
isk markers alone (22). One problem with this approach
s that not all reclassification is necessarily clinically
seful. If a patient is deemed to be at intermediate risk
nd is then reclassified as being at high or low risk, the
linician might find that information helpful. It may not
e known, however, whether or not these reclassifications
re correct for individual subjects. Pencina and colleagues
ntroduced 2 new approaches, namely “net reclassification
mprovement” and “integrated with classification im-
rovement,” which provide quantitative estimates of cor-
ect reclassifications (23). Correct reclassifications are
ssociated with higher predicted risks for cases and lower
redicted risks for noncases. a.6. Usefulness in Motivating Patients or
uiding Therapy
n 1996 the American College of Cardiology Bethesda
onference reviewed the concept of risk stratification, an
pproach that is now standard for identifying the appropri-
te degree of therapeutic or preventive interventions (2).
atients deemed to be at low risk for clinical events are
nlikely to gain substantial benefits from pharmaceutical
nterventions and therefore might best be managed with
ifestyle modifications. Conversely, patients deemed to be at
igh risk for events are more likely to benefit from phar-
acologic interventions and therefore are appropriate can-
idates for intensive risk factor modification efforts. Among
atients at intermediate risk, further testing may be indi-
ated to refine risks and assess the need for treatment.
lthough this model is attractive and has been shown to be
ppropriate in certain situations, there is no definitive
vidence that it directly leads to improved patient outcomes.
urther research is clearly needed, and it is appropriate to
oint out that the risk stratification paradigm has not been
ubjected to rigorous evaluation by randomized trials. In-
eed, the impact of various risk assessment modalities on
atient outcomes is rarely studied and not well documented
n the few studies that have been conducted (24).
.7. Economic Evaluation of Novel Risk Markers
he progressively rising costs of medical care have increased
nterest in documenting the economic effects of new tests
nd therapies. The most basic goal is to estimate the
conomic consequences of a decision to order a new test.
he ultimate goal is to determine whether performing the
est provides sufficient value to justify its use.
A complete economic evaluation of the test has to
ccount for all the subsequent costs induced by ordering the
est, not just the cost of the test itself. The results of the test
hould change subsequent clinical management, which
ight include ordering follow-up tests, starting or stopping
rug therapy, or using a device or procedure. The costs of
hese subsequent clinical management choices must be
ncluded in an “intention-to-test” analysis of the economic
onsequences of the initial decision to use the test. Ideally,
he analysis should be extended to account for clinical events
hat are either averted or caused as a result of the strategy
ased on performing the test.
An example of the economic consequences of testing will
llustrate the importance of these principles. Suppose a
atient with diabetes who has no cardiac symptoms under-
oes a computed tomography (CT) coronary angiogram,
hich reveals obstructive CAD but also leads to contrast-
nduced nephropathy. Further suppose this patient has a
ollow-up invasive coronary angiogram, undergoes insertion
f a coronary stent, and is treated for renal insufficiency. The
osts of all these “downstream events” should be included in
ny economic assessment of the use of CCTA because they
ll resulted from the initial decision to perform the test.
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xceed the cost of the initial test itself.
The cost of any medical intervention has to be placed in
he context of the clinical benefits that the intervention
rovides. In the example of the patient with diabetes,
erhaps the aggressive use of coronary revascularization
ctually extended life expectancy. Cost-effectiveness analysis
rovides a formal framework with which to compare the
linical effectiveness of an intervention (measured in
atient-centered outcomes such as length of life or quality of
ife) with the cost of that intervention. Cost-effectiveness
nalysis has been most commonly applied to the evaluation
f new medical therapies that directly improve clinical
utcomes (e.g., use of bypass surgery to treat CAD).
iagnostic tests do not improve clinical outcomes directly,
owever, and do so only indirectly by changing clinical
anagement decisions, which in turn may improve clinical
utcomes. Thus, determining the cost-effectiveness of a
iagnostic test depends on how effectively the information is
sed and can be evaluated only in the context of available
reatments and how effective those treatments are. A test
hat provides accurate risk information about an untreatable
isease is unlikely to be cost-effective simply because clinical
utcomes cannot be improved by its use.
In general, testing strategies such as those assessed in this
ocument have not included evaluations of the cost and
ost-effectiveness of the tests. Therefore, although this
eneral guidance is offered to the reader as a caveat, the
riting committee was generally unable to find evidence to
upport the cost-effectiveness of any of the tests and testing
pproaches discussed here. Where exceptions were identi-
ed, cost-related information is included. In addition, for
he uncommon examples for which clinical outcomes of
esting strategies were assessed, the writing committee
ncluded that evidence in the assessment of the value of the
isk assessment test.
. Approaches to Risk Stratification
.1. General Approach to Risk Stratification
.1.1. Recommendation for Global Risk Scoring
LASS I
. Global risk scores (such as the Framingham Risk Score [FRS]) that
use multiple traditional cardiovascular risk factors should be ob-
tained for risk assessment in all asymptomatic adults without a
clinical history of CHD. These scores are useful for combining
individual risk factor measurements into a single quantitative esti-
mate of risk that can be used to target preventive interventions (25).
(Level of Evidence: B)
.1.1.1. GENERAL DESCRIPTION
rospective epidemological studies have established, pri-
arily in studies of people 40 years of age, that readily
easured and often modifiable risk factors are associated
ith the development of clinical CHD in asymptomaticndividuals. There are robust prognostic data for each of the eclassic risk factors,” namely, cigarette smoking, cholesterol
evels, blood pressure levels, and diabetes. Data obtained
rom the Framingham Heart Study and other population-
ased cohorts have demonstrated that age, sex, cigarette
moking, level of low-density lipoprotein (LDL) cholesterol
r total cholesterol, diabetes, and levels of blood pressure
an be combined in predictive models to estimate risk of
atal and nonfatal CHD events (26). Beginning in the
990s, a number of global risk prediction instruments were
ntroduced, based on multivariable models that incorporated
isk factor data and clinical events (25–28). These instru-
ents go beyond simple demographics by taking into
ccount modifiable risk markers that are also appropriate
vidence-based targets for preventive interventions. Table 2
ummarizes a sample of published global risk score
nstruments.
Global risk assessment instruments, such as the FRS, are
onsidered valuable in medical practice because clinicians
nd patients may not otherwise accurately assess risk. In
ome survey studies, clinicians presented with scenarios
ere found to overestimate the likelihood of a future major
linical cardiovascular event (29). Other studies have sug-
ested that physicians may also underestimate risk (30–32).
ailure to use global quantitative risk instruments may result
n physicians inappropriately informing patients that they
re at high risk and inappropriately promoting therapeutic
nterventions of modest or questionable benefit or, alterna-
ively, inadequately emphasizing risk when risk is actually
resent.
Global risk scores, although designed to estimate risk
cross a continuous range from 0% to 100%, have most
ommonly been advocated as a method by which patients
an be categorized in broad terms as “low risk,” “interme-
iate risk,” and “high risk.” In general, patients are deemed
o be high risk if they are found to have a global risk
stimate for hard CHD events of at least 20% over 10 years.
he threshold for dividing low risk from intermediate risk is
ot uniform, with some proposing a lower cutoff value of 6%
isk over 10 years, whereas others use a value of 10% over 10
ears (27,33,34). This document, unless otherwise noted,
ses a lower cutoff value of at least 10% and a higher cutoff
f 20% to designate intermediate risk.
The evidence with regard to global risk scores is most
ppropriate for individuals 40 years of age. It is important
o note that there are limited data from Framingham and
ther long-term observational studies on 10-year risk in
oung adults; consequently, it is difficult to estimate 10-year
isk in young adults. This is due to the fact that 10-year risk
n young adults is very rarely impressively elevated, even in
he face of significant risk factors, and thus there are a
imited number of coronary events for calculating risk. As
oted earlier in this document, the long-term or lifetime
isk may be substantially raised by the presence of risk
actors in young adults. Although the earliest age at which
hese risk scores should be used has not been rigorously
stablished, the application of a particular risk score or test
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Texthould not detract from adherence to a healthy lifestyle and
dentification of modifiable risk factors beginning in child-
ood. Therefore, to direct attention to the lifetime signifi-
ance of coronary risk factors in younger adults, the writing
ommittee considered measurement of a global risk score
ossibly worthwhile even in persons as young as age 20.
.1.2. Association With Increased Risk and
ncremental Risk of Additional Risk Factors
number of global risk instruments have been developed
35). In the United States the best known is the FRS,
everal variants of which have been published (25–28,34).
ome include diabetes as a risk factor (25). The version
ublished with the National Cholesterol Education Pro-
ram Adult Treatment Panel (ATP III) report did not
nclude diabetes (27), which was considered to be a CHD
isk equivalent. Some versions of the FRS have focused on
HD death and nonfatal MI as endpoints, whereas a more
ecent version focused on more comprehensive total cardio-
ascular events (27,28,36). A European “SCORE” (System-
tic Coronary Risk Evaluation) was developed based on a
egression model derived from observations of 200,000
dults (37). This model differs from the Framingham model
n a variety of factors, including incorporation of age into a
ime scale and consideration of geographic variability within
uropean countries as the calibration metric (35).
Many of the multivariable coronary risk assessment func-
ions have been evaluated for predictive capability (38). In a
arge number of different cohort studies, multivariable risk
quations typically yielded ROC areas approximately equal
o 0.80, indicating relatively high levels of predictive dis-
able 2. Comparison of a Sample of Global Coronary and Cardi
Framingham SCORE
ample size 5,345 205,178
ge (y) 30 to 74; M: 49 19 to 80; M: 46
ean follow-up (y) 12 13
isk factors
considered
Age, sex, total
cholesterol, HDL
cholesterol,
smoking,
systolic blood
pressure,
antihypertensive
medications
Age, sex, total-HDL
cholesterol ratio,
smoking,
systolic blood
pressure
ndpoints CHD (MI and CHD
death)
Fatal CHD
RLs for risk
calculators
http://hp2010.
nhlbihin.net/
atpiii/calculator.
asp?usertypeprof
http://www.
heartscore.org/
Pages/welcome.
aspx
HD indicates coronary heart disease; CVD, cardiovascular disease; HbA1C, hemoglobin A1C; H
ean; MI, myocardial infarction; PROCAM, Münster Heart Study; and SCORE, Systematic Coronrimination. Data from the NHANES (National Health snd Nutrition Examination Surveys) prospective cohort
tudy were used to study how well a Framingham-type risk
odel could predict first-time fatal and nonfatal CVD
vents (39). Risk factors included in the model to assess risk
f CVD were age, systolic blood pressure, smoking status,
otal cholesterol, reported diabetes status, and current treat-
ent for hypertension. In women the risk model was useful
or predicting events, with a C statistic of 0.829. In men the
esults were similar (C statistic, 0.78). Results such as these
re typical for a Framingham-like risk assessment model in
ost populations, but there has been concern that global
isk scores developed in one population may not be appli-
able to other populations (24). The FRS has been validated
n several external populations, but in some cases it has
equired a “prevalence correction” to recalibrate the scores to
eflect lower population prevalence of disease (25). Al-
hough global risk scores have often been found to have
statistics indicating that the score is useful for discrimi-
ation, the focus on 10-year risk estimates in clinical
edicine makes many risk scores less useful for clinical
ecision making in most younger male patients and most
omen (40–42).
Some large-scale investigations have suggested that
early 90% of the population-attributable risk for CAD can
e ascribed to traditional biological and psychosocial risk
actors (43). However, none of the current risk models,
ased only on traditional risk factors such as the FRS, are
ble to discriminate risk to an extent that would eliminate
aterial uncertainty of risk for individual patients being
een by individual clinicians. Even in a global risk model
cular Risk Scores
ROCAM (Men) Reynolds (Women) Reynolds (Men)
9 24,558 10,724
o 65; M: 47 45; M: 52 50; M: 63
10.2 10.8
, LDL cholesterol,
DL cholesterol,
oking, systolic
ood pressure,
mily history,
abetes,
iglycerides
Age, HbA1C (with
diabetes),
smoking, systolic
blood pressure,
total cholesterol,
HDL cholesterol,
hsCRP, parental
history of MI at
60 y of age
Age, systolic blood
pressure, total
cholesterol, HDL
cholesterol, smoking,
hsCRP, parental
history of MI at 60 y
of age
l/nonfatal MI or
dden cardiac
ath (CHD and
VD combined)
MI, ischemic
stroke, coronary
revascularization,
cardiovascular
death (CHD and
CVD combined)
MI, stroke, coronary
revascularization,
cardiovascular death
(CHD and CVD
combined)
://www.chd-
skforce.com/
ronary_risk_
sessment.html
http://www.reynolds
riskscore.org/
http://www.reynolds
riskscore.org/
h-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; M,
k Evaluation.ovas
P
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CV Risk Guideline: Full Text December 14/21, 2010:e50–103OC curve of as high as 80% in some studies (38), there is
onsiderable overlap in risk scores between people who are
ltimately found to be affected versus those found to be
naffected. Hence, a number of investigators argue for
ngoing discovery and investigation of newer risk factors
nd predictive risk markers to improve the ability of clini-
ians to discriminate risk among their individual patients
20,44,45).
In summary, a FRS, or a similar type of multivariable
redictive score based on traditional cardiovascular risk
actors, is highly predictive of cardiovascular events. Given
he familiarity of health professionals and the general public
ith the traditional risk factors and the proven efficacy of
nterventions for modifiable factors in these models, the
riting committee agreed with many previous clinical prac-
ice guidelines that a “Framingham-like” risk score should
e the basic risk assessment strategy to use for all asymp-
omatic adult patients (46–53). Additional risk markers
hould be assessed for their ability to improve on risk
ssessment beyond prediction from the multivariable global
isk score. The writing committee felt that it is reasonable to
dvocate global risk score measures coincident with
uideline-supported measurements of blood pressure or
holesterol beginning at age 20 and then every 5 years
hereafter (27). The writing committee also acknowledged
hat some investigators advocate a shift in the risk assess-
ent focus to ‘lifetime risk” of CHD, but to date, evidence
s sparse on how best to incorporate estimates of lifetime
isk into clinical management (11). Another approach to the
ong-term risk estimation problem in younger adults was
ecently presented by the Framingham Study investigators
s the “30-Year Risk of Cardiovascular Disease” (54).
.2. Family History and Genomics
.2.1. Recommendation for Family History
LASS I
. Family history of atherothrombotic CVD should be obtained for
cardiovascular risk assessment in all asymptomatic adults (22,55).
(Level of Evidence: B)
.2.1.1. ASSOCIATION WITH INCREASED CARDIOVASCULAR RISK AND
NCREMENTAL RISK
family history of premature (early-onset) atherothrom-
otic CVD, defined most often as occurring in a first-degree
ale relative 55 years of age or in a first-degree female
elative 65 years of age, has long been considered a risk
actor for CVD. Even a positive parental history that is not
remature increases the risk of CVD in offspring (56). The
mportance of family history is not surprising because the
isk factors for CVD, including hypertension, dyslipidemia,
iabetes, obesity, and smoking behavior, are in part herita-
le (19,57–62). In addition, lifestyle habits such as diet,
xercise, and smoking are in part learned behaviors influ-
nced by family patterns. However, studies examining
arents, siblings, twins, and second-degree relatives have
emonstrated that the 1.5- to 2.0-fold RR of family history persists even after adjusting for coexistent risk factors
56,63–66). The risk associated with a positive family
istory for CVD is observed in individuals of White
uropean, African American, Hispanic, and Japanese de-
cent (67–69). The strength of the risk for an individual
ncreases with younger age of onset, increasing numbers of
elatives affected, and the relative’s genealogical proximity
56,63,66,70). Although the prevalence of a positive family
istory ranges from 14% to 35% in the general population,
lmost 75% of those with premature CHD have a positive
amily history, underscoring opportunities for prevention
71,72).
The reliability of self-reported family history is imperfect
71,73). To address recall bias, investigators from the
ramingham Study used validated parental data and re-
orted that although the negative predictive value for
eports of premature MI and CHD death was superb
90%), the positive predictive value for validated events
as only fair (28% to 66%) (73). Similarly, the Health
amily Tree Study found that the positive predictive value
f a positive family history of CHD was 67%, but the
egative predictive value was excellent at 96% (70,71). The
ensitivity of self-reported family history is 70% (71,73).
n addition, there has been increasing attention to improv-
ng the collection of family history through standardized
uestionnaires and online resources (74).
Family history modestly improves risk stratification. In
he Framingham Heart Study, the inclusion of a positive
amily history improved ability to predict CVD (the multi-
ariable model C statistic [ROC] increased from 0.82 to
.83). Family history appeared to aid in reclassifying indi-
iduals and was most useful in persons at intermediate risk
third and fourth multivariable predicted risk quintile) of
VD (63,64).
.2.1.2. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
he ability of family history of CVD to motivate patients is
ot definitively established. Some studies have reported that
ersons with a positive family history of CHD were more
otivated to modify their risk factors (75). In the CARDIA
Coronary Artery Risk Development in Young Adults)
tudy, however, young adults did not self-initiate or modify
heir CVD risk factors after a change in family history of
eart attack or stroke (76). Intensive interventions targeting
hose with a positive family history of CHD can improve
isk factors; however, the sustainability of such interventions
nd their influence on CHD events has been more difficult
o prove. For instance, a randomized study of black patients
ith a family history of premature CHD demonstrated that
ntensive community-based multiple risk factor intervention
esulted in significant reductions in global CHD risk (im-
rovements in cholesterol and blood pressure) compared
ith an enhanced primary care group (77). However, the
ustainability of such efforts was disappointing; 5 years after
ompletion, the previously observed improved risk factor
rofile of the intensive community-based group was no
l
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vents (78).
.2.2. Genotypes: Common Genetic Variants for
oronary Heart Disease
.2.2.1. RECOMMENDATION FOR GENOMIC TESTING
LASS III: NO BENEFIT
. Genotype testing for CHD risk assessment in asymptomatic adults
is not recommended (79,80). (Level of Evidence: B)
.2.2.2. ASSOCIATION WITH INCREASED CARDIOVASCULAR RISK AND
NCREMENTAL RISK
HD is typically due to the complex interplay between
nvironmental factors and multiple common genetic vari-
nts (minor allele frequency 5%) with small or very
odest effects (OR typically 1.2 to 1.5, and rarely 2.0)
81). The first widely replicated genetic variant for CHD
as discovered by a genomewide association study on
hromosome 9p21.3 (82–84). The 1.3- to 2.0-fold in-
reased risk for MI observed with single nucleotide poly-
orphisms (SNPs) from the 9p21.3 genomic region has
een observed in persons of various ethnicities, including
uropean, Asian, and Hispanic descent, but thus far it has
ot been replicated in African Americans, which may relate
o patterns of haplotype diversity in the genomic region
82–87). The mechanisms underlying the 9p21.3 associa-
ion with CHD remain unclear, although the variants are
djacent to CDKN2A, ARF, and CDKN2B, which are
enes thought to regulate senescence and apoptosis (88).
ariants tested in the 9p21.3 region (rs10757274, GG
ersus AA) were associated with a HR for incident CHD of
.6 for incident CHD in men participating in the NPHS II
Northwick Park Heart Study II) (89). The addition of the
enotype to a model based on traditional CVD risk factors
id not significantly improve risk discrimination (area under
he ROC, 0.62 [95% CI 0.58 to 0.66] to 0.64 [95% CI 0.60
o 0.68]; p0.14). However, the genotype resulted in better
odel fit (likelihood ratio, p0.01) and shifted 13.5% of
he men into a more accurate risk category (89).
In the Women’s Genome Health Study (n22,129), an
NP at chromosome 9p21.3 was associated with an in-
reased hazard for incident CVD; however, the SNP did
ot enhance model discrimination (C index, 0.807 to 0.809)
r net reclassification when added to the Reynolds risk
core, which includes family history (79). In another study,
nvestigators reported that a genome score including 9 SNPs
ssociated with serum lipid levels was associated with an
ncreased risk of CVD events, but the score did not improve
odel discrimination (ROC, 0.80 for the model with and
ithout the score). Furthermore, investigators reported that
aving a parent or sibling with a history of MI conferred a
0% increased risk of incident cardiovascular events (HR
.52; 95% CI 1.17 to 1.97; p0.002) in a model including
he genotype score (90). Family history may integrate the
omplexity of interacting genomic and environmental fac-
ors shared by family members. Many other SNPs have been leported as risk markers for future CHD events. Given the
ery small OR and the small incremental risk information of
he individual polymorphisms, the writing committee
udged that genomic tests for CHD risk currently offer no
roven benefit in risk assessment when added to a global
asic risk score such as the FRS.
.2.2.3. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
tudies assessing whether genotype testing enhances moti-
ation and success with adherence to recommended lifestyle
nd medical therapies demonstrate mixed results (80,91).
mokers given scenarios of genotype testing information
eport more motivation to quit but lower levels of perceived
ontrol and similar success with smoking cessation at 1 year
92,93). In another study, persons who agreed to receive
enotype data (GSTM1 SNP) were more likely to abstain
rom cigarette smoking at 12-month follow-up than those
ho declined the test, regardless of whether they tested
ositive or negative for the risk SNP (94).
No data are available as to whether the results of genotype
esting alter management or improve outcomes for preven-
ion of CHD (92,95). Despite the uncertainty about the
linical implications of most genotypic markers for CHD,
here is widespread direct-to-consumer marketing of these
ests (95). A concern is that advertisements and genetic
nformation provided by for-profit genomic testing services
ay overstate claims and confuse or frighten consumers. In
ddition, regulation of the companies and provision for
enetic counseling is sporadic (95). Thus, the writing
ommittee was aware of no benefit of genotype testing, and
iven the limited benefit in terms of risk assessment, the
riting committee concluded that these types of tests should
ot be done at this time.
.3. Lipoprotein and Apolipoprotein Assessments
.3.1. Recommendation for Lipoprotein and
polipoprotein Assessments
LASS III: NO BENEFIT
. Measurement of lipid parameters, including lipoproteins, apoli-
poproteins, particle size, and density, beyond a standard fasting
lipid profile is not recommended for cardiovascular risk assessment
in asymptomatic adults (96). (Level of Evidence: C)
.3.2. Assessment of Lipoprotein Concentrations,
ther Lipoprotein Parameters, and Modified Lipids
eyond the standard fasting lipid profile (total cholesterol,
igh-density lipoprotein (HDL) cholesterol, LDL choles-
erol, and triglycerides), additional measurements of lipid
arameters or modified lipids have been proposed to extend
he risk factor–cardiovascular prediction relationship. Each
DL particle contains 1 molecule of apolipoprotein B
often referred to as ApoB); thus, the concentration of
poB directly reflects LDL particle numbers. The relation-
hip between apolipoprotein A (often referred to as ApoA)
nd HDL is less direct. Several techniques directly measure
ipid particle numbers or their size distribution. All lipid
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CV Risk Guideline: Full Text December 14/21, 2010:e50–103articles (e.g., LDL or HDL) are present in the circulation
n a range of sizes. Oxidative modification of lipid particles
ccurs and appears to influence their atherogenic potential.
Non-HDL cholesterol, meaning cholesterol transported
n LDL and very-low-density lipoprotein, reflects the total
oncentration of atherogenic particles, is closely related to
article number, and is simply calculated as the difference
etween total cholesterol and HDL-cholesterol blood con-
entrations. Particle size is similarly closely related to HDL
nd triglyceride concentrations. High concentrations of
riglycerides lead to triglyceride enrichment of LDL or
DL. Subsequent particle modification by hepatic lipase
eads to reduction of particle size and increased density,
roperties associated with heightened atherogenic potential.
reatment guidelines for the consideration of pharmaco-
herapy and the therapeutic targets for non-HDL choles-
erol are 30 mg/dL higher than the thresholds for LDL
holesterol (27).
.3.3. Risk Prediction Relationships Beyond
tandard Risk Factors
any so-called “advanced lipid measures” of the type
iscussed above, particularly apolipoprotein concentrations
nd particle number, have been shown by some, but not all,
tudies to be associated with cardiovascular outcomes com-
arable to standard lipid concentrations (43,97). For exam-
le, the EPIC-Norfolk (European Prospective Investigation
nto Cancer and Nutrition) study among apparently healthy
ndividuals showed a 34% increased odds for future CHD
ssociated with the highest quartile of LDL particle number
fter controlling for the FRS (97). However, this was similar
o non-HDL cholesterol (38% increased odds); thus, no
elative benefit of particle number determinations was
ound. A recent systematic review observed that no study
as reported the incremental predictive value of LDL
ubfractions beyond that of traditional cardiovascular risk
actors, nor evaluated their independent test performance
for example, sensitivity and specificity) (96). Although the
istribution of advanced lipid measures is different in men
nd women (and is also related to menopausal status), the
utcome relationships are present for both men and women
n similar magnitude (98,99).
Two studies have specifically evaluated the predictive
erformance of ApoB or nuclear magnetic resonance LDL-
article concentration for risk reclassification of asymptom-
tic individuals compared with standard lipids. In the
ramingham Heart Study, little additional risk information
as obtained from ApoB or ApoB/A-1 ratio compared with
he total/HDL-cholesterol ratio (100). Thus, evidence that
hese more “advanced” lipid measures improve predictive
apacity beyond standard lipid measurements is lacking
101).
The role of lipoprotein(a) [Lp(a)] in risk assessment has
eceived attention as a potential additional risk marker. In
he Emerging Risk Factors Collaboration, circulating con-
entration of Lp(a), a large glycoprotein attached to anDL-like particle, was assessed for its relationship with risk
f major vascular and nonvascular outcomes. Long-term
rospective studies that recorded Lp(a) concentration and
ubsequent major vascular morbidity and/or cause-specific
ortality published between January 1970 and March 2009
ere identified through electronic and other means (102).
nformation was available from 126 634 participants in 36
rospective studies and spanned 1.3 million person-years of
ollow-up. Lp(a) concentration was weakly correlated with
everal conventional vascular risk factors and highly consis-
ent within individuals over several years. In the 24 cohort
tudies, the risk ratio for CHD was 1.13 per standard
eviation for higher Lp(a) (95% CI 1.09 to 1.18) after
djustment for age, sex, lipid levels, and other conventional
isk factors. The corresponding adjusted risk ratios were
.10 (95% CI 1.02 to 1.18) for ischemic stroke, 1.01 (95%
I 0.98 to 1.05) for the aggregate of nonvascular deaths,
.00 (95% CI 0.97 to 1.04) for cancer deaths, and 1.00 (95%
I 0.95 to 1.06) for nonvascular deaths other than cancer.
his study demonstrated that there are continuous, inde-
endent, but modest associations of Lp(a) concentration
ith risk of CHD and stroke. As with previous individual
eports, associations were only modest in degree, and
etailed information on incremental risk prediction beyond
raditional risk factors is still lacking. There have also
een, and continue to be, concerns about measurement
nd standardization of measurement of Lp(a) in clinical
ettings (103). The writing committee therefore con-
luded that measurement of Lp(a) did not merit consid-
ration for cardiovascular risk assessment in the asymp-
omatic individual.
.3.4. Usefulness in Motivating Patients or
uiding Therapy
dditional lipid measures, beyond the standard lipid profile,
ary in their interassay agreement, laboratory standardiza-
ion, and established reference ranges and are generally
imited by the absence of clear thresholds for initiation of
reatment, therapeutic targets, or unique treatments beyond
hose already recommended by lipid treatment guidelines
irected by the standard lipid profile (104).
.3.5. Evidence for Improved Net Health Outcomes
here is no evidence that the assessment of additional lipid
arameters leads to improved net health outcomes, and thus
he cost-effectiveness of these measures cannot be assessed.
.4. Other Circulating Blood Markers and
ssociated Conditions
.4.1. Recommendation for Measurement of
atriuretic Peptides
LASS III: NO BENEFIT
. Measurement of natriuretic peptides is not recommended for CHD riskassessment in asymptomatic adults (105). (Level of Evidence: B)
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trial natriuretic peptide, B-type natriuretic peptide, and
heir precursors (N-terminal-proatrial natriuretic peptide)
re emerging markers of prevalent CVD. Natriuretic pep-
ides are released from the myocardium in response to
ncreased wall stress and have been shown to be helpful in
he diagnosis of heart failure among symptomatic patients,
s well as having prognostic value in patients with estab-
ished heart failure. Levels of natriuretic peptides have also
een demonstrated to be markers of prognosis in patients
able 3. Cardiovascular Disease Risk Assessment for B-Type N
Study Name Population N Age
ramingham, MA
(108)
Ambulatory adults,
3.4% with prior MI
3,352 59
openhagen,
Denmark (109)
Random sample of
general population
without CVD
626 67.9
lostrup,
Denmark (107)
General population
without CVD
1,994 30 to 60
ancho Bernardo,
CA (110)
General population
without CVD
805 77
lasgow,
Scotland (111)
Random sample of
general
population, some
with prevalent
CHD
1,252 50.4
uopio, Finland
(112)
Kuopio Ischemic
Heart Disease Risk
Factor Study,
longitudinal
population-based
sample of men
905 55.8 (46 to 6
lmsted County,
MN (106)
General population
without congestive
heart failure or
renal failure
2,042 62 10
almo, Sweden
(20)
General population
without CVD
5,067 58
ppsala, Sweden
(113)
General population
without CVD
661 71
NP indicates B-type natriuretic peptide; CHD, coronary heart disease; CV, cardiovascular; CV
atriuretic peptide; proBNP, B-type natriuretic peptide; SD, standard deviation; and TIA, transienith either acute coronary syndromes or stable CAD. sRecent studies have examined whether natriuretic pep-
ides also predict the development of CVD in the asymp-
omatic, healthy adult population. The evidence from sev-
ral prospective cohort investigations (Table 3) suggests that
igher levels of natriuretic peptides predict the development
f incident CVD, including heart failure, stroke, and atrial
brillation.
There is some evidence that natriuretic peptides are
tronger predictors of the development of heart failure than
f incident coronary events (106–108), and other studies
retic Peptide
Follow-Up
(y) Event Main Findings
5.2 Major CVD (CHD death,
MI, stroke, heart
failure, coronary
insufficiency)
CHD death: HR 1.27/SD of
NT-proANP, HR 1.41/SD
of BNP; major event: HR
1.28/SD of NT-proANP,
1.30/SD of BNP
5.0 Death; major CVD
(CHD death, MI,
stroke, heart failure,
unstable angina, TIA)
Death: HR 1.43/SD of NT-
proBNP; CV event: HR
1.92/SD (all
multivariable adjusted)
9.4 CV events (CVD death,
MI, stroke)
CV events: HR 1.58/SD
NT-proBNP; evidence of
interaction with age
6.8 Death; CV death Death: HR 1.74/SD of NT-
proBNP; CV events: HR
1.85/SD of NT-proBNP
(multivariable adjusted)
4.0 All-cause mortality Death: HR 2.2 for BNP
17.9 pg/mL
(multivariable adjusted
for age, sex, prior CHD)
10 Death, CV death, CHD
death
Multivariable-adjusted
HR/SD change:
proANP proBNP
1.35 1.26
1.48 1.41
1.52 1.44
5.6 All-cause mortality Mortality somewhat assay
dependent (Shionogi,
Biosite, NT-proBNP),
adjusted mortality
ranged from HR 1.63 to
1.39, somewhat
attenuated if adjusted
for echocardiographic
measurements
12.8 CV events (CV death,
MI, stroke)
Multivariable-adjusted HR/
SD change for BNP 1.22,
C index improvement,
0.004 (p0.12)
10 CV death Multivariable-adjusted HR/
SD change for NT-pro-
BNP 1.58, C index
improvement,
0.034 (p0.20)
iovascular disease; HR, hazard ratio; MI, myocardial infarction; NT, N-terminal; proANP, atrial
mic attack.atriu
5)uggest that their prognostic value is attenuated after ad-
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CV Risk Guideline: Full Text December 14/21, 2010:e50–103ustment for echocardiographic measures such as left ven-
ricular mass and left ventricular diameter. The mechanism
or these associations is as yet undetermined, and it is
ossible that natriuretic peptides are markers of left ventric-
lar hypertrophy (LVH) or subclinical myocardial damage
rom hypertension, ischemia, or both.
Most prospective cohort studies (Table 3) report that
atriuretic peptides predict prognosis and do so indepen-
ent of other cardiac risk markers. Although these cohort
tudies suggest that natriuretic peptide levels convey prog-
ostic information, the value of that information has not yet
een rigorously evaluated by use of the C index or measures
f risk reclassification (105). Consequently, the value of
atriuretic peptide measurement in the assessment of car-
iovascular risk among asymptomatic adults free of CAD or
eart failure is not definitively known. Because of the
bsence of such data, the writing committee does not
ecommend measurement of natriuretic peptides for risk
ssessment in the asymptomatic adult.
.4.1.2. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
here have been no studies evaluating whether natriuretic
eptides have value in motivating healthy patients, guiding
reatment, or improving outcomes (there is some evidence
n these points in populations of patients with heart failure
ut not in asymptomatic adults).
.4.2. Recommendations for Measurement of
-Reactive Protein
LASS IIa
. In men 50 years of age or older or women 60 years of age or older
with LDL cholesterol less than 130 mg/dL; not on lipid-lowering,
hormone replacement, or immunosuppressant therapy; without
clinical CHD, diabetes, chronic kidney disease, severe inflammatory
conditions, or contraindications to statins, measurement of CRP can
be useful in the selection of patients for statin therapy (114). (Level
of Evidence: B)
LASS IIb
. In asymptomatic intermediate-risk men 50 years of age or younger
or women 60 years of age or younger, measurement of CRPmay be
reasonable for cardiovascular risk assessment (22,115). (Level of
Evidence: B)
LASS III: NO BENEFIT
. In asymptomatic high-risk adults, measurement of CRP is not
recommended for cardiovascular risk assessment (116). (Level of
Evidence: B)
. In low-risk men younger than 50 years of age or women 60 years of
age or younger, measurement of CRP is not recommended for
cardiovascular risk assessment (22,115). (Level of Evidence: B)
.4.2.1. ASSOCIATION WITH INCREASED CARDIOVASCULAR RISK AND
NCREMENTAL RISK PREDICTION
nflammation is considered to be central to the pathogenesis
f atherosclerosis, and numerous inflammatory biomarkers
ave been evaluated as risk factors or risk markers for CVD.
he most intensively studied inflammatory biomarker asso-
iated with CVD risk is high-sensitivity CRP (hsCRP).
RP is associated with an adjusted increased risk for wevelopment of other CVD risk factors, including incident
iabetes, incident weight gain, and new-onset hypertension
117–119). Interventions that improve CVD risk factors,
uch as exercise, weight loss, smoking cessation, statins, and
ntihypertensive treatments, are associated with lowering of
RP (120–124). CRP concentrations are fairly constant
nd repeatable over time (125,126). In the JUPITER
Justification for the Use of Statins in Prevention: an
ntervention Trial Evaluating Rosuvastatin) study partici-
ants randomly assigned to placebo, intraclass correlation
as 0.54 (95% CI 0.53 to 0.55), which was similar to blood
ressure and LDL cholesterol (127). Prior guidelines have
ecommended measuring CRP twice, particularly in persons
ith intercurrent illness if elevated when first measured
128).
A meta-analysis of 20 observational studies (both pro-
pective and case-control) demonstrated that CRP levels
re associated with incident CHD, with an adjusted odds
atio (comparing persons in the top versus bottom third) of
.45 (95% CI 1.25 to 1.68) (129). CRP levels have been
ssociated with incident CHD in both men and women and
ersons of European, Japanese, and American Indian de-
cents (22,130–132). CRP is also associated with other
orms of CVD, including incident stroke, PAD, heart
ailure, atrial fibrillation, sudden death, and all-cause mor-
ality (133–137). Despite consistent evidence that CRP
evels above the population median value are associated with
ncreased risk of CHD, it has not been determined whether
RP is causally related to CHD (138–142).
CRP modestly improved risk prediction of CVD end-
oints in some studies beyond that accounted for by
tandard CVD risk factor testing (143). However, after
ccounting for standard CVD risk factors in many studies,
odel discrimination (area under the ROC) had no or
inimal improvement (144,145). As noted earlier in this
uideline, statisticians recently proposed that measures of
eclassification should be used to evaluate new biomarkers in
ddition to metrics of test discrimination, calibration, and
ther standard approaches to evaluate new markers. Data
rom the Physicians’ Health Study and Framingham Heart
tudy have shown that CRP measurements improve reclas-
ification of an individual’s risk beyond standard risk pre-
iction models (115,145). However, a meta-analysis includ-
ng data from the NPHS II and the Edinburgh Artery
tudy concluded that the ability of CRP to reclassify risk
orrectly was modest and inconsistent (144). As with most
ew biomarker tests, whether knowledge of CRP levels
mproves patients’ motivation to adhere to CHD lifestyle or
harmacological treatments is unknown.
Recent clinical trial data provided evidence that measure-
ent of CRP in highly preselected patients may have
mportant clinical implications. The JUPITER trial was a
andomized, double-blind, placebo-controlled trial of the
se of rosuvastatin (20 mg/d) versus placebo in the primary
revention of CVD events in men and women (n17,802)
ithout diabetes with LDL cholesterol 130 mg/dL and
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ears, rosuvastatin was associated with a significant reduc-
ion in the primary endpoint of cardiovascular events. The
R for rosuvastatin versus placebo was 0.56 (95% CI 0.46
o 0.69; p0.00001), and the event rate was 0.77 versus
.36 per 100 person-years of follow-up (147). The reduction
n endpoints was consistent across prespecified subgroups,
ncluding men and women, older and younger persons,
hites and non-whites, and persons at higher and lower risk
s measured by the FRS (147). Within JUPITER, 17 men
nd 31 women would need to be treated for 5 years to
revent the endpoint of MI, stroke, revascularization, or
eath (148). For persons at low risk (FRS 10), 37 persons
ould need to be treated for 5 years to prevent the same
revious endpoints (148).
The JUPITER trial leaves a number of questions unan-
wered about use of CRP levels in cardiovascular risk
ssessment. Specifically, JUPITER was not a trial of CRP
149), because persons with unknown or low CRP concen-
rations were not studied. Cost-effectiveness of CRP testing
n an asymptomatic population, beyond the specific patient
opulation of JUPITER, has not yet been studied.
.4.3. Metabolic: Hemoglobin A1C
.4.3.1. RECOMMENDATION FOR MEASUREMENT OF HEMOGLOBIN A1C
LASS IIb
. Measurement of hemoglobin A1C (HbA1C) may be reasonable for
cardiovascular risk assessment in asymptomatic adults without a
diagnosis of diabetes (150–155). (Level of Evidence: B)
.4.3.2. GENERAL DESCRIPTION
bA1C is a blood test useful for providing an estimate of
verage glycemic control over several months. The test has
een shown to be predictive of new-onset diabetes (156). A
ystematic review and a recent international expert commit-
ee have suggested that HbA1C might be effective to screen
or the presence of diabetes (157,158). The ADA has
ndorsed the use of HbA1C to diagnose diabetes (HbA1C
6.5%) and to identify persons at increased risk for diabetes
HbA1C, 5.7% to 6.4%) (158).
.4.3.3. ASSOCIATION WITH CARDIOVASCULAR RISK IN PERSONS
ITHOUT DIABETES
n 1 study, in individuals without established diabetes, for
very 1 percentage point higher HbA1C concentration,
here was an adjusted 40% higher risk of CHD (p0.002)
150). HbA1C was associated with an increased risk of
ncident stroke in the Japanese (159). Whether or not
bA1C improves CVD risk discrimination and reclassifi-
ation is less certain. Some studies have reported that
bA1C does not improve prediction (156) or reclassifica-
ion (160). However, other studies have observed that in
ersons without diabetes, higher levels of HbA1C are
ssociated with an increased risk of CVD (161). In a 2010
eport using data from the ARIC (Atherosclerosis Risk in
ommunities) study, it was demonstrated that in persons
ithout diabetes, prediction models including HbA1C mevels were associated with improved risk prediction, dis-
rimination, and reclassification compared with prediction
odels that included standard risk factors and fasting
lucose (155). This study is the strongest evidence available
oncerning the potential value of HbA1C for CVD risk
ssessment in asymptomatic persons without diabetes. As
ith most other novel markers of CVD risk, it is unknown
hether HbA1C is useful for motivating individuals to
dhere to preventive interventions in the absence of diag-
osed diabetes.
.4.4. Urinary Albumin Excretion
.4.4.1. RECOMMENDATIONS FOR TESTING FOR MICROALBUMINURIA
LASS IIa
. In asymptomatic adults with hypertension or diabetes, urinalysis to
detect microalbuminuria is reasonable for cardiovascular risk as-
sessment (162–164). (Level of Evidence: B)
LASS IIb
. In asymptomatic adults at intermediate risk without hypertension or
diabetes, urinalysis to detect microalbuminuria might be reason-
able for cardiovascular risk assessment (165). (Level of Evidence: B)
.4.4.2. GENERAL DESCRIPTION
rinalysis for microalbuminuria is widely available, inex-
ensive, and associated with cardiovascular events (166).
he ADA recommends annual urinalysis for detection of
icroalbuminuria in persons with diabetes mellitus (167). A
ecent meta-analysis showed that increased risk of CVD
ssociated with microalbuminuria was present in persons
oth with and without diabetes (166). However, standard-
zation of the measurement of urine albumin across labora-
ories is suboptimal (168,169). It is logistically difficult for
ost patients to perform 24-hour urine collection, but
tudies have demonstrated that the first morning (“spot
rine”) urinary albumin–to-creatinine ratio has a similar
bility to predict CVD events (170). On the basis of the
rinary albumin–to-creatinine ratio on a morning spot urine
ample, microalbuminuria is defined as 30 to 300 mg/g and
acroalbuminuria is defined as 300 mg/g (171). Blacks
nd Mexican Americans have a higher prevalence of albu-
inuria than their Caucasian counterparts, regardless of
iabetes status (172). Longitudinal data from the
HANES, between 1988–1994 and 1999–2004, found
hat the prevalence of microalbuminuria had increased from
bout 7.1% to 8.2% (p0.01) (173).
Excretion of urinary albumin in the microalbuminuria
ange is considered a candidate for CVD risk biomarker for
everal reasons. Standard CVD risk factors are associated
ith microalbuminuria (174,175). Microalbuminuria is as-
ociated with incident hypertension, progression to a higher
lood pressure category, and incident diabetes (176,177).
icroalbuminuria and diabetes each appear to influence the
ther’s progression (178). Furthermore, microalbuminuria
as been associated with other novel risk factors for CVD,
uch as impaired endothelial function and inflammatory
arkers such as CRP (179–181). Microalbuminuria is
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arly CVD (182).
.4.4.3. ASSOCIATION WITH CARDIOVASCULAR RISK
meta-analysis of 26 cohort studies with 169,949 partici-
ants reported that after accounting for standard CVD risk
actors, there was a dose–response relationship between
lbuminuria and risk of CHD (166). Compared with
ndividuals without albuminuria, macroalbuminuria was
ssociated with a doubling of risk (RR 2.17; 95% CI 1.87 to
.52), and microalbuminuria was associated with a nearly
0% greater risk (RR 1.47; 95% CI 1.30 to 1.66) of CHD
166). The increased risk of CVD was present across many
ifferent subgroups, including persons with and without
ypertension, with and without diabetes, and with and
ithout decreased estimated glomerular filtration rate
165,166,183). The prognostic importance of microalbu-
inuria also has been observed in older and younger
ndividuals and ethnic minorities, including American In-
ians, South Asians, and African Carribbeans (166,
84–186).
In studies examining the incremental yield of adding
rinary albumin excretion in the microalbuminuria range to
tandard CVD risk factors for CVD risk prediction, the
ramingham Heart Study and the Cardiovascular Health
tudy observed only minor improvements in the C statistic
175,187). However, the Cardiovascular Health Study ob-
erved that the urinary albumin–to-creatinine ratio did assist
ith risk reclassification. Persons at intermediate risk (pre-
icted 5-year Framingham risk of 5% to 10%) with a urinary
lbumin–to-creatinine ratio 30 mg/g had a substantially
igher 5-year risk of CHD than those with a ratio of 30
g/g (20.1% versus 6.3%, respectively) (175).
.4.4.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
he writing committee is unaware of data that suggest that
nowledge of albuminuria improves patient motivation or
dherence to preventive therapies.
.4.5. Lipoprotein-Associated Phospholipase A2
.4.5.1. RECOMMENDATION FOR LIPOPROTEIN-ASSOCIATED
HOSPHOLIPASE A2
LASS IIb
. Lipoprotein-associated phospholipase A2 (Lp-PLA2) might be rea-
sonable for cardiovascular risk assessment in intermediate-risk
asymptomatic adults (188–191). (Level of Evidence: B)
.4.5.2. GENERAL DESCRIPTION
p-PLA2, or platelet-activating factor acetylhydrolase, is
proatherogenic enzyme produced by macrophages and
ymphocytes (192). Lp-PLA2 hydrolyzes oxidized phos-
holipids in LDL, leading to the generation of lysophos-
hatidylcholine, oxidized nonesterified fatty acids, as well
s other active phospholipids and inflammatory media-
ors (192). Reported clinical correlates of increasing
p-PLA2 mass and activity include advanced age, maleex, smoking, and LDL; Lp-PLA2 activity also wasnversely associated with HDL (193). There have been
nexplained ethnic differences in Lp-PLA2 concentra-
ions; adjusting for standard CVD risk factors, Lp-PLA2
ctivity was higher in white and Hispanic participants
han in black participants (194).
.4.5.3. ASSOCIATION WITH CARDIOVASCULAR RISK
n a meta-analysis of 14 studies, Lp-PLA2 was associated
ith an adjusted OR for CVD of 1.60 (95% CI 1.36 to
.89) (190). Although there was moderate heterogeneity
cross studies in the meta-analysis, there was no signif-
cant difference between Lp-PLA2 mass and activity for
isk prediction (190). A number of studies have reported
hat the increased CVD risk of Lp-PLA2 remains after
djusting for CRP, in addition to standard CVD risk
actors (188,189,191). Several studies have examined
hether Lp-PLA2 improves risk discrimination over and
bove models accounting for standard risk factors. Both
he ARIC study and Rancho Bernardo study investiga-
ors observed that Lp-PLA2 was associated with a
tatistically significant increment in the area under the
urve (AUC) (p0.05), although the increments were
mall (for the ARIC study, 0.774, increased to 0.780 with
he addition of Lp-PLA2; for the Rancho Bernardo
tudy, change in ROC was 0.595 to 0.617) (189,195). In
modest-sized study (n765), Lp-PLA2 was associated
ith a nonsignificant 9.5% net reclassification (196).
hese reports indicate that Lp-PLA2 has modest incre-
ental risk prediction information, meaning its use in
ntermediate-risk patients might be reasonable. There is
ittle information about the predictive capability of Lp-
LA2 in ethnic minorities, because the vast majority of
tudies reported to date have been conducted in whites of
uropean ancestry (190).
.4.5.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
resently there is no information about whether Lp-PLA2
oncentrations are clinically effective for motivating pa-
ients, guiding treatment, or improving outcomes. Random-
zed studies have demonstrated that lipid-lowering ther-
pies reduce Lp-PLA2, although there may be some
ariability by medication type (197,198). Drugs under
evelopment that specifically inhibit Lp-PLA2 activity
ave been shown to lower Lp-PLA2 activity and inflam-
atory markers (199).
.5. Cardiac and Vascular Tests for Risk
ssessment in Asymptomatic Adults
.5.1. Resting Electrocardiogram
.5.1.1. RECOMMENDATIONS FOR RESTING ELECTROCARDIOGRAM
LASS IIa
. A resting electrocardiogram (ECG) is reasonable for cardiovascular
risk assessment in asymptomatic adults with hypertension or dia-betes (200,201). (Level of Evidence: C)
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. A resting ECG may be considered for cardiovascular risk assess-
ment in asymptomatic adults without hypertension or diabetes
(202-204). (Level of Evidence: C)
.5.1.2. GENERAL DESCRIPTION
pidemiological studies have shown that abnormalities on a
esting 12-lead ECG are predictive of subsequent mortality
nd cardiovascular events among asymptomatic adults
200,202,205,206). Specific electrocardiographic findings
hat have been linked to cardiovascular risk in population-
ased cohorts and asymptomatic patients with hypertension
nclude LVH (especially when accompanied by repolariza-
ion changes), QRS prolongation, ST-segment depression,
-wave inversion, and pathological Q waves (202,207–211).
everal studies suggest that subtle electrocardiographic ab-
ormalities detectable only by computer analysis may also be
ssociated with increased risk (212–214).
The 12-lead resting ECG may provide information about
ther CVD, particularly cardiac arrhythmias, by document-
ng extra systoles, atrial fibrillation, ventricular pre-
able 4. Sample of Longitudinal Studies Reporting the Indepen
symptomatic Populations
Primary
Measurement(s)
First Author
(Year, Country) Type of Events
Follo
(y
ovacode major and
minor
abnormalities
Denes (2007, US)
(216)
Composite of
cardiovascular
events
3
ooling project,
major and minor
abnormalities*
DeBacquer (1998,
Belgium) (205)
CHD and CVD
mortality,
all-cause
mortality
10
VH with ST-
depression and
negative T wave
Larsen (2002, Denmark)
(210)
MI, incident
CHD, CVD
mortality
21
nrecognized MI Sigurdsson (1995,
Iceland) (211)
Death from
CHD, stroke,
and all
causes
10
inor ST-T
abnormalities
Daviglus (1999, US)
(207)
All-cause, CHD,
and CVD
mortality
29
igital ECG measures Gorodeski (2009, US)
(212)
All-cause
mortality
11
Major abnormalities include ST-segment depression, T-wave inversion, complete or second-degre
brillation or flutter. Minor abnormalities include nonpathological Q wave, a left- or right-axis de
CHD indicates coronary heart disease; CVD, cardiovascular disease; ECG, electrocardiogram
entricular hypertrophy; MI, myocardial infarction; and US, United States.xcitation, or prolonged QT interval. Many cardiomyopa- mhies display nonspecific electrocardiographic changes.
here has been interest in electrocardiographic abnormali-
ies that may be predictive of sudden cardiac death in young,
eemingly healthy athletes (215). The usefulness of screen-
ng with ECGs for these disorders is beyond the scope of
he current document.
.5.1.3. ASSOCIATION WITH INCREASED RISK AND INCREMENTAL RISK
able 4 presents a sample of longitudinal studies that
eport independent predictive value of different resting
lectrocardiographic measures in asymptomatic popula-
ions. A number of classification schemes have been
escribed that may be useful for risk stratification. An
xample is the Novacode criteria, which divide electro-
ardiographic abnormalities into major and minor types
216). Major abnormalities include atrial fibrillation or
trial flutter, high-grade atrioventricular (AV) block, AV
issociation, complete bundle-branch block, pathological
waves, isolated ischemic abnormalities, LVH with
ccompanying repolarization abnormalities, and arrhyth-
Predictive Value of Resting ECG Measures in
Population
Characteristics
(No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
Women in the
Women’s
Health
Initiative trial
(14,749)
64 For minor abnormalities, HR 1.6;
for major abnormalities HR 3.0;
C index increased by 0.05
compared with FRS
Population-based
sample (5,208
men, 4,746
women)
49 (men),
48 (women)
Major ECG abnormalities predicted
all-cause mortality (HR 1.8), CVD
mortality (HR 3.3), and CHD
mortality (HR 2.3). Minor ECG
abnormalities were not
predictive.
Population-based
sample (5,243
men, 6,391
women)
53 Predictive of MI (HR 1.9), incident
CHD (HR 2.2), and cardiovascular
mortality (HR 1.9)
Icelandic Heart
Association
Preventive
Clinic, all men
(9,141)
52-58 Predictive of CHD death (HR 4.6)
and all-cause death (HR 2.7)
Men employed at
an electric
company
(1,673)
48 Predictive of death due to CHD
(HR 1.7), CVD (HR 1.4), and all
causes (HR 1.3)
Ambulatory
patients
without known
CVD (18,964)
51 Combined ECG measures predictive
of all-cause death (HR 1.4,
comparing 75th to 25th
percentiles; C index increased by
0.04 compared with standard
predictors; relative IDI increased
by 3%)
ventricular block, complete left or right bundle-branch block, frequent premature beats, and atrial
QRS high voltage, borderline ST-segment depression, T-wave flattening, and QRS low voltage.
Framingham risk score; HR, hazard ratio; IDI, integrated discrimination improvement; LVH, leftdent
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econd-degree AV block, borderline prolongation of the
RS interval, prolonged repolarization, isolated minor
-wave and ST-T abnormalities, LVH by voltage only,
eft atrial enlargement, frequent atrial or ventricular
remature beats, or fascicular blocks. Electrocardio-
raphic findings have also been combined with echocar-
iography to improve risk stratification in patients with
ypertension (201).
Abnormal Q waves on the ECG may indicate clinically
nrecognized or “silent” MI. In the Framingham Study, as
any as one quarter of nonfatal MIs were found only
hrough ECG changes (217). In a number of population
tudies, Q waves on the ECG indicate a higher cardiovas-
ular risk (202,211).
Electrocardiographic LVH and associated repolariza-
ion abnormalities have been predictive of subsequent
ardiovascular risk in numerous prospective epidemiolog-
cal studies, including the Framingham Study. LVH on a
esting ECG may indicate more severe or poorly con-
rolled hypertension, which in turn increases cardiovas-
ular risk (218). In 1 large randomized trial that specif-
cally focused on patients with electrocardiographic
VH, regression of left ventricular mass as assessed by
CGs was a predictor of a lower risk of major cardio-
ascular events (219).
Few studies have evaluated the ability of the resting
CG to improve discrimination and reclassify risk com-
ared with standard risk assessment. In 14,749 asymp-
omatic, postmenopausal women enrolled in the Wom-
n’s Health Initiative, the resting ECG increased the C
tatistic over the FRS from 0.69 to 0.74 for prediction of
HD events (216). In 18,964 Cleveland Clinic patients
ithout known CVD, the resting ECG similarly in-
reased the C statistic by 0.04 and modestly improved
eclassification (relative integrated discrimination im-
rovement, 3%, p0.001) (212).
.5.1.4. USEFULNESS IN MOTIVATING PATIENTS, GUIDING THERAPY, AND
MPROVING OUTCOMES
here have been no randomized trials demonstrating that
ndings on a resting ECG can be used to motivate better
ifestyle behaviors in the asymptomatic adult. One large
andomized trial offered suggestive evidence that electro-
ardiographic assessment of left ventricular mass may be
seful for guiding antihypertensive therapy, because re-
ression of electrocardiographic LVH was associated
ith reduced risk for sudden death (220), atrial fibrilla-
ion (219), heart failure (221), major CVD events (200),
nd diabetes (222). However, no randomized trial has
irectly addressed this question (223). One policy-based
ntervention study found that an ECG-based screening
rogram for competitive athletes may have reduced the
opulation risk of sudden cardiac death among young
dults (224). o.5.2. Resting Echocardiography for Left Ventricular
tructure and Function and Left Ventricular
ypertrophy: Transthoracic Echocardiography
.5.2.1. RECOMMENDATIONS FOR TRANSTHORACIC ECHOCARDIOGRAPHY
LASS IIb
. Echocardiography to detect LVH may be considered for cardiovas-
cular risk assessment in asymptomatic adults with hypertension
(225,226). (Level of Evidence: B)
LASS III: NO BENEFIT
. Echocardiography is not recommended for cardiovascular risk as-
sessment of CHD in asymptomatic adults without hypertension.
(Level of Evidence: C)
.5.2.2. LEFT VENTRICULAR FUNCTION
ransthoracic echocardiography is a diagnostic modality
idely used in cardiology practice. There are no echocar-
iographic findings with high sensitivity and specificity for
he diagnosis of CHD in the absence of ischemia or
nfarction. Segmental wall motion abnormalities are the
ost common echocardiographic manifestation of CHD
ut are only present if there is active or recent (stunning)
schemia or there has been prior infarction. Moreover,
egmental wall motion abnormalities do not uniformly
epresent ischemic territories caused by occlusive CAD,
ecause they may also be present in patients with nonisch-
mic cardiomyopathies. Additional manifestations of CHD
nclude ischemic mitral regurgitation, global reduction in
eft ventricular systolic function, Doppler findings charac-
eristic of diastolic dysfunction, and right ventricular dys-
unction. However, none of these findings has sufficient
ensitivity or specificity to be useful for screening or risk
ssessment in the asymptomatic patient at possible risk for
HD. Given the lack of evidence of risk assessment benefit
n the general population, it was the consensus of the
riting committee that echocardiography should not be
erformed for risk assessment in the asymptomatic adult
ithout hypertension.
.5.2.3. LEFT VENTRICULAR HYPERTROPHY
VH develops in response to varying stimuli and may be
hysiological in the setting of athletic training and preg-
ancy or pathological in response to pressure or volume
verload, myocardial injury, or underlying genetic muta-
ions. The pathophysiological mechanism for higher cardio-
ascular mortality in the setting of LVH is not completely
nderstood, although studies have demonstrated decreased
ow reserve and greater susceptibility to injury associated
ith ischemia and infarction (227). The methodology for
VH measurement by echocardiography and the cut points
or definition of LVH vary widely among studies. There is
lso wide variability as to whether LVH is indexed to body
urface area, height, or weight (227,228). A recent meta-
nalysis of 34 studies showed that 19 different criteria were
sed, leading to differences in the prevalence of LVH (229).
he writing committee recommends the use of the meth-
dology and cut points defined by the ASE (230). Separate
c
s
s
s
C
(
b
s
F
m
t
A
L
M
e
i
e
e
w
m
I
a
D
g
t
t
d
h
m
o
m
d
h
i
h
F
n
e
c
u
i
g
h
h
2
A
e
i
m
o
w
c
r
L
t
t
m
v
b
(
i
(
g
r
u
l
b
E
g
m
c
(
r
(
o
p
t
a
f
L
r
i
(
t
c
g
o
p
t
2
2
I
C
1
2
C
t
d
e69JACC Vol. 56, No. 25, 2010 Greenland et al.
December 14/21, 2010:e50–103 CV Risk Guideline: Full Textut points should be applied to men and women. Further
tudies may suggest that the definition of pathological LVH
hould be specific to race as well as sex. A recent study
howed that athletic hypertrophy in African/Afro-
aribbeans (blacks) was greater than in whites (231).
LVH has been shown to be predictive of cardiovascular
including stroke) and all-cause mortality, independent of
lood pressure, and across all racial groups that have been
tudied. In the predominantly white population of the
ramingham Study, for every 50 g/m2 higher left ventricular
ass index, there was a RR of death of 1.73 (95% CI 1.19
o 2.52) independent of blood pressure level (232). In the
frican-American population enrolled in the ARIC study,
VH conferred an increased risk for CVD events (nonfatal
I, cardiac death, coronary revascularization, and stroke)
ven after adjusting for other risk factors with a HR of 1.88
n men and 1.92 in women (228). Among American Indians
nrolled in the Strong Heart Study (64% female, mean age
qual to 58), the prevalence of LVH on echocardiography
as 9.5% and conferred a 7-fold increase in cardiovascular
ortality and a 4-fold increase in all-cause mortality (201).
n this study, echocardiographic evidence of LVH had
dditive discriminatory power over ECG evidence of LVH.
ata from a Hispanic population (226) are similarly sug-
estive of the association of LVH and cardiovascular mor-
ality. The association of LVH and mortality in many of
hese studies cannot be attributed only to the risk of
eveloping atherosclerotic CHD, because patients with
ypertrophic cardiomyopathy who die suddenly may be
isclassified. Recent estimates suggest a 1 in 500 prevalence
f hypertrophic cardiomyopathy in the population, which
ay contribute to the association between LVH and car-
iovascular (including stroke) and all-cause mortality.
LVH is considered evidence of target organ damage in
ypertension according to JNC 7 (233). The epidemiolog-
cal association between pathological hypertrophy and CVD
as also been studied in hypertensive populations (201,226).
or example, in the MAVI (Massa Ventricolare sinistra
ell’Ipertensione) study of patients with uncomplicated
ssential hypertension, there was a 40% higher risk of
ardiovascular events for each 39 g/m2 greater left ventric-
lar mass index (225). Left ventricular architecture is also an
mportant variable related to risk, with most studies sug-
esting that the presence of concentric rather than eccentric
ypertrophy in the hypertensive population carries the
ighest risk.
.5.2.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
lthough the finding of increased left ventricular mass on
chocardiography could be envisioned to guide selection or
ntensity of therapy in hypertensive patients, JNC 7 recom-
endations do not risk stratify patients on the basis of target
rgan damage (233). Given the adverse prognosis associated
ith LVH in hypertension, further studies examined the
omparative efficacy of specific antihypertensive agents in
egressing LVH as well as survival benefits associated with aVH regression, but there was a lack of consistency among
he trials. In a meta-analysis of 39 trials of antihypertensive
herapy, angiotensin-converting enzyme inhibitors were the
ost effective agents, leading to a 13.3% reduction in left
entricular mass compared with 9.3% for calcium channel
lockers, 6.8% for diuretics, and 5.5% for beta blockers
234). In a comparison of enalapril and long-acting nifed-
pine in patients with essential hypertension, the PRESERVE
Prospective Randomized Enalapril Study Evaluating Re-
ression of Ventricular Enlargement) trial, a prospective
andomized enalapril study evaluating regression of ventric-
lar enlargement, systolic and diastolic pressures as well as
eft ventricular mass were reduced to a similar degree with
oth agents (235). The LIFE (Losartan Intervention For
ndpoint Reduction in Hypertension) trial echocardio-
raphic substudy demonstrated superior left ventricular
ass reduction (21.7 g/m2) in patients treated with losartan
ompared with patients treated with atenolol (17.7 g/m2)
218). Diuretics demonstrated superiority in treating LVH
egression over alternative agents in both the TOMHS
Treatment of Mild Hypertension Study) and Department
f Veterans Affairs Cooperative Study Group on Antihy-
ertensive Agents, using chlorthalidone and hydrochlor-
hiazide, respectively (236,237).
LVH regression does not adversely affect cardiac function
nd may be associated with improvements in diastolic
unction. Most importantly, patients who demonstrate
VH regression on antihypertensive therapy have a lower
ate of cardiovascular events than those who do not,
ndependent of the extent of blood pressure control
238,239).
Despite these observations, there have been no trials that
arget antihypertensive therapy to regress echocardiographi-
ally detected LVH, and thus the results continue to
enerate hypotheses.
No studies have examined whether a patient’s knowledge
f echocardiographic results demonstrating LVH will im-
rove adherence to lifestyle modifications or pharmacologic
reatment of hypertension.
.5.3. Carotid Intima-Media Thickness on Ultrasound
.5.3.1. RECOMMENDATION FOR MEASUREMENT OF CAROTID
NTIMA-MEDIA THICKNESS
LASS IIa
. Measurement of carotid artery IMT is reasonable for cardiovascular
risk assessment in asymptomatic adults at intermediate risk
(240,241). Published recommendations on required equipment,
technical approach, and operator training and experience for per-
formance of the test must be carefully followed to achieve high-
quality results (241). (Level of Evidence: B)
.5.3.2. GENERAL DESCRIPTION
arotid IMT testing is a noninvasive, nonionizing radiation
est using ultrasound imaging of the carotid artery wall to
efine the combined thickness of the intimal and medial
rterial wall components. It is most commonly measured in
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CV Risk Guideline: Full Text December 14/21, 2010:e50–103he far wall of the common carotid artery; however, it can
lso be measured in the near wall and other carotid segments
bulb, internal). With well-trained operators, the test has
een shown to be highly accurate with excellent intertest
nd interobserver reproducibility primarily in research set-
ings and less commonly in practitioner-based settings
242). The available data on risk associated with carotid
MT are drawn almost exclusively from research settings
sing highly standardized protocols. The use of common
arotid IMT as a standard site of measurement has been
roposed due to its inherent greater reproducibility and
bility to refine the cardiovascular risk prediction. Published
ecommendations on the required equipment, technical
pproach, and operator training and experience for perfor-
ance of the test must be carefully followed to achieve
igh-quality results (241,243). There is a need for provider
ompetency and lab accreditation standards to ensure qual-
ty imaging. An elevated level of carotid IMT is commonly
ited as a level that surpasses the population-based 75th
ercentile value, but this must be identified specific to a
articular carotid arterial segment (e.g., common or internal
arotid artery) and ultrasound methodology for which tables
re available (241).
.5.3.3. INDEPENDENT RELATIONSHIP BEYOND STANDARD RISK FACTORS
arotid IMT has been independently associated with future
isk for ischemic coronary events and stroke in middle-aged
nd older individuals (244). The risk of incident CHD
vents increases in a continuous fashion as carotid IMT
ncreases (RR increases approximately 15% per 0.10-mm
ncrease in carotid IMT); thus, measurement of carotid
MT has been shown in research studies to be a marker of
isk for atherosclerotic CVD. Furthermore, the finding of
therosclerotic plaque, operationally defined as a focal in-
rease in thickness 50% of the surrounding IMT, in-
reases the predicted CAD risk at any level of carotid IMT
245). These values were determined after adjustment for
raditional CVD risk factors.
The relationship between carotid IMT and incident
HD events was initially noted in the Kuopio Ischemic
eart Disease Risk Factor study, in which risk of future MI
n Finnish men increased by 11% for every 0.1-mm incre-
ent in carotid IMT (246). For carotid IMT values 1
m, there was a 2-fold greater risk of acute MI over 3 years.
he ARIC study showed that for every 0.19-mm increment
n carotid IMT, risk of death or MI increased by 36% in
iddle-aged patients (45 to 65 years of age) (247). CHD
isk was almost 2-fold greater in men with mean carotid
MT 1 mm and even greater in women (RR 5.0). Not all
tudies, however, have shown differences between men and
omen in the predictive value of carotid IMT. For example,
he Rotterdam study found that the risk of CHD events and
arotid IMT was similar among men and women (248).
The association between carotid IMT and incidence of
I and stroke has been noted in older populations andther high-risk populations. In the Cardiovascular Health atudy, the RR for MI, adjusted for age, gender, and
tandard cardiovascular risk factors, was 3.15 (95% CI 2.19
o 4.52) when an average IMT was used for the common
arotid and internal carotid arteries and when comparing
he highest quintile versus the lowest quintile. These dif-
erences held true for patients with and without known
VD (249). Among middle-aged adults with diabetes
ellitus in the ARIC study, an IMT1 mm was associated
ith an increase in the ROC AUC from 0.711 to 0.724
mong women and 0.680 to 0.698 in men (250) when this
levated IMT was included in traditional risk factor predic-
ive models. Similarly, in the Cardiovascular Health Study,
he incidence of CAD was shown to increase from 2.5% to
.5% per year among patients with diabetes with subclinical
ascular disease (251).
Carotid IMT measurement can lead to improved cardio-
ascular risk prediction and reclassification. In the ARIC
tudy, 13,145 individuals were followed for approximately
5 years for incident hard coronary events and revascular-
zation. Carotid IMT measurements, which included both
MT and carotid plaque, were incremental to traditional
isk factors for prediction of incident cardiovascular events.
n particular, among intermediate-risk patients (10% to
0%, 10-year estimated risk group), the addition of carotid
MT and plaque information led to clinical net reclassifi-
ation improvement of approximately 9.9% (240).
Comparisons of carotid IMT with coronary calcium
coring as methods to modify cardiovascular risk assessment
ave been made in both middle-aged (MESA) and older
ndividuals (Cardiovascular Health Study). Each study
howed that carotid IMT was an independent predictor of
ardiovascular outcomes. Coronary calcium was a relatively
tronger predictor for coronary outcomes, whereas carotid
MT was a stronger predictor of stroke in MESA (252). In
ontrast, significant and similar magnitude relationships to
ardiovascular outcomes (HRs for fourth quartile versus first
uartile for each test, approximately 2.1) were observed in
he Cardiovascular Health Study for both tests (253). Given
he discrepancy between these available studies, the data are
nsufficient to conclude whether these tests are clinically
quivalent or not. Thus, at this time, test selection in clinical
ractice is better guided by local and patient factors such as
xpertise, cost, and patient preference.
Epidemiological studies demonstrate that IMT typically
rogresses at an average rate of 0.03 mm per year, and the
ate of progression appears to be related to risk of cardio-
ascular event (254). Progression can be slowed by
holesterol-lowering drugs (statins and niacin) and other
isk factor modifications (e.g., control of blood pressure).
owever, serial scanning of carotid IMT is challenging in
ndividual patients across brief time horizons due to vari-
bility in measurement in relation to the rate of disease
rogression and is therefore not recommended in clinical
ettings.
Images of subclinical atherosclerosis are hypothesized to
lter patient behavior, but the evidence is insufficient (255).
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he finding of increased carotid IMT should clinically
uide selection or intensity of therapy. However, evidence is
acking regarding whether measurement of carotid IMT
lters outcome (Table 5). Clinical tools integrating carotid
MT within global risk scoring systems are not available.
.5.3.5. EVIDENCE FOR IMPROVED NET HEALTH OUTCOMES
he incremental value of carotid IMT and cost-
ffectiveness beyond that available from standard risk as-
essments to improve overall patient outcomes is not
stablished.
.5.4. Brachial/Peripheral Flow-Mediated Dilation
.5.4.1. RECOMMENDATION FOR BRACHIAL/PERIPHERAL
LOW-MEDIATED DILATION
LASS III: NO BENEFIT
. Peripheral arterial flow-mediated dilation (FMD) studies are not
recommended for cardiovascular risk assessment in asymptomatic
adults (256,257). (Level of Evidence: B)
.5.4.2. GENERAL DESCRIPTION
eripheral arterial FMD is a noninvasive measure of endo-
helial function. Augmented flow is produced by a sustained
eriod (typically 4 to 5 min) of forearm compression
ccompanied by vascular occlusion followed by release. In
he setting of healthy endothelium, increased flow stimu-
ates release of nitric oxide, inducing local brachial artery
asodilation. The degree of dilation can be measured using
igh-resolution ultrasound. The technique requires a highly
killed sonographer, highly standardized measurement con-
itions (including time of day, temperature, drug adminis-
ration), and suitable ultrasound machine. Many examiners
lso use specialized computer software to semiautomatically
uantitate the brachial artery diameter. Considerable vari-
bility exists for values of FMD determined by different
nvestigators, even in similar patient populations, suggesting
echnical challenges with the measurement (258). Impor-
able 5. Summary of Prospective Studies Evaluating Carotid IM
Patie
Study,
Participants
Carotid IMT
Measurement Clinical Events
F
IHD, 905 (112) CCA/carotid bifurcation* Fatal/nonfatal MI 1
RIC, 12,841
(247)
CCA/ICA/carotid
bifurcation†
Fatal/nonfatal MI
HS, 4,476 (249) CCA/ICA‡ MI/stroke
otterdam Study,
7,983 (248)
CCA¶ MI/stroke
ESA, 6,698
(252)
CCA Cardiovascular
events
Mean carotid IMT; †Mean far wall, internal carotids, and bifurcation; ‡Mean of CCA and ICA; §O
arotid IMT; ¶Mean CCA; #OR is for risk of MI only.
ARIC indicates Atherosclerosis Risk in Communities study; CCA, common carotid artery; CHD,
rtery; IMT, intima-media thickness; KIHD, Kuopio Ischemic Heart Disease study; MESA, Multi-Eant technical factors influencing FMD are duration of forearm occlusion and the location of the occluding cuff, but
any other factors are also important, as mentioned above.
n research settings, brachial artery FMD has been shown to
orrelate with invasive measures of coronary artery FMD
fter adenosine triphosphate infusion, suggesting that pe-
ipheral FMD may be a suitable substitute for invasive
oronary endothelial function testing (257). FMD also
orrelates with other noninvasive measures of cardiovascular
isk, including CRP, carotid IMT, and measures of arterial
tiffness.
PAT is a second method of assessing postocclusion
asodilation. This method uses bilateral finger cuffs that
ense pulse wave volume. After a 5-minute flow occlusion in
arm, the resulting augmentation of pulse volume in the
cclusion arm is compared with the control arm, yielding a
AT ratio. The PAT ratio provides information similar to
MD (256,259).
.5.4.3. ASSOCIATION WITH INCREASED RISK AND
NCREMENTAL PREDICTION
any studies have documented a relationship between
MD, PAT, and traditional CVD risk factors. FMD and
AT ratios are lower (abnormal) in subjects with greater
umbers of risk factors or higher levels of FRS. Diabetes
nd smoking have the most powerful associations with
bnormal FMD. A meta-regression analysis of 211 publi-
ations reported on 399 populations where both FMD and
raditional risk factors were available (260). By design, many
f these populations had existing CVD. The relationship
etween FMD and risk factors was most clear in the
ategory with the lowest baseline risk. In this group, for
ach percentage point higher FRS, FMD was lower by
.42%. In populations with an intermediate or high FRS,
MD was not related to the score. This finding fits with the
ypothesis that FMD is an early marker of vascular dys-
unction. Once multiple risk factors are present, FMD may
ecome so impaired that additional risk factors do not
d Incident Coronary Events in Patients Without Known CHD
tails
Up
Age (y) Sex
Carotid IMT
Increment
(mm) OR (95% CI)
3 y 42 to 60 Men 0.1 1.11 (1.06 to 1.16)
45 to 64 Men
Women
0.19
0.19
1.36 (1.23 to 1.51)
1.69 (1.50 to 1.90)
65 Men and
women
0.20 1.46 (1.33 to 1.60)§
55 Men
Women
0.163
0.163
1.56 (1.12 to 2.18)#
1.44 (1.00 to 2.08)#
45 to 64 Men and
women
0.19 1.30 (1.10 to 1.40)
sk for MI and coronary death only; OR for MI and stroke was 1.47 (95% CI 1.37 to 1.67); CCA,
ry heart disease; CHS, Cardiovascular Health Study; CI, confidence interval; ICA, internal carotid
tudy of Atherosclerosis; MI, myocardial infarction; and OR, odds ratio.T an
nt De
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(y)
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eneration Cohort (n1,957) (261). In a stepwise multi-
ariable regression model, PAT ratio was inversely related to
ale sex, body mass index, total/HDL-cholesterol ratio,
iabetes, smoking, and lipid-lowering treatment. In this
tudy, hypertension was not related to PAT.
It is unclear whether these measures of peripheral endo-
helial health provide incremental predictive information
hen controlling for traditional risk factors. The relation-
hip between FMD and incident cardiovascular events was
eported in a population-based cohort of older adults (262).
n the Cardiovascular Health Study, 2,792 (2,791 with
omplete data) adults aged 72 to 98 years underwent FMD
easures (262). During 5-year follow-up, 24.1% of these
ubjects had events. At study entry, 76% of this population
n2,125) was free of known CVD. In the subset without
nown CVD at entry, the predictive value of FMD (after
djustment for age, gender, diabetes, blood pressure, cho-
esterol, and HMG-CoA [3-hydroxy-3-methylglutaryl-
oenzyme A] reductase inhibitor use) was directionally
imilar to the whole population but failed to achieve
tatistical significance (p0.08). The addition of brachial
MD to the predictive model containing the classical
ardiovascular risk factors increased the AUC by a net
hange of only 0.001, and the p value for the increase was
ot significant (area under receiver operating statistic 0.841
ersus 0.842). NOMAS (Northern Manhattan Study), a
maller multiethnic, prospective cohort study of 842 subjects
ree of CVD examined the relationship of FMD to 36-
onth cardiovascular events (263). Although FMD was
ssociated with the occurrence of future events (HR 1.12 for
very 1% decrease in FMD), the association was no longer
tatistically significant when traditional cardiovascular risk
actors were included in a multivariable analysis. In contrast,
study of 2264 asymptomatic postmenopausal women
ound that FMD was independently related to cardiovascu-
ar events (RR 1.12; 95% CI 1.04 to 2.00; p0.001) when
ncluded in a model with traditional risk factors (264). No
easures of reclassification were reported in this study.
.5.4.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
here is no evidence that arterial FMD studies are useful for
otivating asymptomatic persons to adhere to preventive
herapies.
In a study of 400 hypertensive postmenopausal women
ollowed up for an average of 67 months (265), endothelial
unction was measured as FMD of the brachial artery at
aseline and at 6 months after initiation of blood pressure
ontrol. After 6 months of treatment, FMD had not
hanged (10% relative to baseline) in 150 (37.5%) of the
00 women, whereas it had significantly improved (10%
elative to baseline) in the remaining 250 women (62.5%).
uring follow-up, failure to have an improved FMD at 6
onths was an independent predictor of nonfatal cardio-
ascular events requiring hospitalization. This study dem-
nstrates that a significant improvement in endothelial munction may be obtained after 6 months of antihypertensive
herapy and also appears to identify patients who may have
more favorable prognosis.
Due to the limited data available, the writing committee
oncluded that it was premature to recommend serial FMD
easurements to monitor treatment effects. In addition, due
o the technical challenges of standardizing measurement of
MD and the relatively modest evidence of incremental
hange in risk assessment, measurement for risk assessment
as not regarded as appropriate for risk assessment in the
symptomatic adult.
.5.4.5. CHANGES IN PATIENT OUTCOMES
o date, there are no published trials evaluating the impact
f specific therapy on clinical outcome in patients identified
s having abnormal peripheral endothelial function.
.5.5. Pulse Wave Velocity and Other Arterial
bnormalities: Measures of Arterial Stiffness
.5.5.1. RECOMMENDATION FOR SPECIFIC MEASURES OF
RTERIAL STIFFNESS
LASS III: NO BENEFIT
. Measures of arterial stiffness outside of research settings are not
recommended for cardiovascular risk assessment in asymptomatic
adults. (Level of Evidence: C)
.5.5.2. DESCRIPTION OF SPECIFIC MEASURES OF ARTERIAL STIFFNESS
rterial stiffness is a consequence of arteriosclerosis, the
rocess of arterial wall thickening, and loss of elasticity that
ccurs with onset of vascular disease and advancing age.
esides pulse pressure (the numeric difference between the
ystolic and diastolic blood pressures), multiple other spe-
ific measures of arterial stiffness have been described
98,266,267). The most commonly studied measures of
rterial stiffness are aortic pulse wave velocity (PWV) and
ulse wave analyses such as the aortic augmentation index
266).
Because blood is a noncompressible fluid, transmission of
he arterial pressure wave occurs along the arterial wall and
s influenced by the biomechanical properties of the arterial
all. When the arteries are stiffened, the pulse wave is
ropagated at an increased velocity, and increased PWV is
herefore correlated with stiffness of the arteries. Factors
ssociated with PWV include advancing age as well as the
ong-term effects of cardiovascular risk factors on the
tructure and function of the arterial wall. PWV is generally
easured using applanation tonometry but can also be
easured by Doppler ultrasound or magnetic resonance
maging (MRI). MRI is more costly and therefore is
ypically not used for testing in asymptomatic persons.
Pulse wave analysis is based on the concept that the
ressure wave is partially reflected back toward the aorta at
arious points of discontinuity in arterial elasticity. Appla-
ation tonometry is considered a relatively simple and
eproducible method of collecting data for pulse wave
nalysis in research settings. The most commonly reported
easure in pulse wave analysis is expressed as a fraction of
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Texthe central pulse pressure, called the aortic augmentation
ndex. The augmentation index is said to be most useful in
atients under the age of 60 years (266). Both pulse wave
nalysis and PWV are typically determined by commercial
evices that perform the analyses based on proprietary
nalytic algorithms (267).
Although predictive information (see below and Table 6)
uggests a potential clinical role for measures of arterial
tiffness, there are a number of technical problems that the
riting committee believed would restrict the applicability
f measures of arterial stiffness predominantly to research
ettings at this time (266,267). For measures of arterial
tiffness to be incorporated into clinical practice, measure-
ent protocols must be well standardized, quality control
rocedures established, and risk-defining thresholds identi-
ed (266). Reproducibility is a problem, as is operator
ependence, both of which limit the generalizability of
able 6. Longitudinal Studies Reporting the Independent Predi
Primary
Measurement
Type
First Author
(Year, Country) Type of Events
Follow-Up
(y)
ortic PWV Meaume (2001,
France) (268)
CV mortality 2.5
D (strain) as
primary measure
Stork (2004,
the Netherlands)
(269)
CV and all-cause
mortality
4.0
ortic PWV Sutton-Tyrrell (2005,
US) (270)
CV mortality and
events
4.6
ortic PWV Shokawa (2005,
Japan) (271)
CVD mortality 10
mbulatory arterial
stiffness index
Dolan (2006,
Ireland) (272)
CVD mortality 5.3
ortic PWV Willum-Hansen
(2006, Denmark)
(273)
Fatal and
nonfatal CVD
and CHD
9.4
mbulatory arterial
stiffness index
Hansen (2006,
Denmark) (274)
Fatal and
nonfatal CVD
and stroke
9.4
arotid-femoral
PWV index
Mattace-Raso
(2006,
the Netherlands)
(275)
CVD, CHD,
stroke,
all-cause
4.1
PP versus BPP Roman (2007, US)
(276)
CVD, fatal and
nonfatal
4.8
D, CPP, BPP Leone (2008,
France) (277)
CHD, fatal and
nonfatal
4
PP and BPP Pini (2008, Italy)
(278)
Total CV events
(fatal and
nonfatal)
8
PP indicates brachial pulse pressure; CD, carotid distension; CHD, coronary heart disease; CI,
azard ratio; NS, nonsignificant; PP, pulse pressure; PWV, pulse wave velocity; Q, quartile; RR,ndings derived from research studies. Additional technical honcerns include the need to standardize room temperature,
ime of day of testing, keeping the patient at rest for at least
0 minutes before measurements are recorded, and careful
ttention to timing of drug and caffeine intake (267). The
riting committee felt that the technical concerns make
rterial stiffness tests less suitable for addition to the clinical
ractice of risk assessment in asymptomatic adults due to
roblems with measurement and data collection.
.5.5.3. EVIDENCE ON THE ASSOCIATION WITH INCREASED
ARDIOVASCULAR RISK AND INCREMENTAL RISK
rom the standpoint of predictive studies within general
healthy” populations, measures that have been studied are
he PWV, ambulatory arterial stiffness index, and carotid
ulse pressure (versus brachial pulse pressure). Predictive
esults in general populations are summarized for 11 longi-
udinal studies in Table 6. Although a few of these studies
Value of Arterial Stiffness in Asymptomatic Populations
pulation Characteristics
(No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
ly men and women
e 70 y) (141)
87 1.19 (95% CI 1.03 to 1.37)
for total CVD mortality
(top decile)
ly men (367) 78 No stiffness measure
associated with outcomes
ly, both sexes (2,488) in
alth ABC study
55 RR 1.15 to 1.30; p0.019
for Q4:Q1 for CHD; RR
2.6; p0.004 for stroke
Q4:Q1
ral population, both sexes
2)
63.7 Top 40%: 4.2 (95% CI 1.39
to 12.96; p0.01)
ral population, both sexes,
s 16 to 96 y (11,291)
54.6 1.16 (95% CI 1.05 to 1.27) in
fully adjusted model for
total CVD death
ral population (1,678),
h sexes, ages 40 to 70 y
51 HR 1.15 (95% CI 1.01 to
1.30) per 1 SD increase for
all endpoints
ral population (1,678),
h sexes, ages 40 to 70 y
51 HR 1.6 (95% CI 1.14 to
2.28; p0.007) for stroke,
but NS for CHD and CVD
hy elderly, both sexes
35); Rotterdam study
71.7 1.9 to 2.0 for T3:1 for CVD,
CHD, stroke
hy American Indians, both
es (2,403), Strong Heart
dy
63 Aortic PP, 1.12 per
10 mm Hg, p0.008
unity elderly (age 65 y)
37), Three-City study
73.2 CD, 2.0 (95% CI 1.27 to
3.17) for T3:T1; CPP, 2.1
(95% CI 1.24 to 3.70) for
T3:T1; BPP, 2.1 (95% CI
1.38 to 3.40) for T3:T1
unity elderly (age 65 y)
3)
73 BPP, NS; CPP HR 1.23 (95%
CI 1.11 to 1.38; p0.001)
per 10 mm Hg
nce interval; CPP, carotid pulse pressure; CV, cardiovascular; CVD, cardiovascular disease; HR,
risk; SD, standard deviation; T, tertile; and US, United States.ctive
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CV Risk Guideline: Full Text December 14/21, 2010:e50–103rterial stiffness, most studies indicated predictive capability
hat is additive to standard risk factors, including (in some
ases) systolic and diastolic blood pressures as well as
nkle-brachial index (ABI). In some studies, but not all,
Rs have been higher for stroke risk than for CAD risk. No
tudies have directly compared these measures of CVD risk
ith other measures of “subclinical” CVD such as arterial
MT or CAC score. HRs have generally been in the very
odest predictive range of 1.1 to 1.3 for various measures of
rterial stiffness and CHD outcomes. Information on
hanges in the C statistic or other measures of incremental
isk stratification has generally not been reported.
.5.5.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
o information has been reported on any of these topics in
ell-conducted studies of populations of healthy adults.
.5.6. Recommendation for Measurement of
nkle-Brachial Index
LASS IIa
. Measurement of ABI is reasonable for cardiovascular risk assess-
ment in asymptomatic adults at intermediate risk (279). (Level of
Evidence: B)
.5.6.1. GENERAL DESCRIPTION
he ABI is an office-based test to check for the presence of
AD. It is performed by Doppler measurement of blood
ressure in all 4 extremities at the brachial, posterior tibial,
nd dorsalis pedis arteries. The highest lower-extremity
lood pressure is divided by the highest of the upper-
xtremity blood pressures, with a value of 0.9 indicating
he presence of PAD, which is defined as 50% stenosis.
hen defined in this way, the ABI has both a high
ensitivity and specificity for anatomic stenosis. In addition
o signifying PAD, an abnormally low ABI has also been
hown to be a predictor of cardiovascular events. Interme-
iate values (0.9 to 1.1) also have a graded association with
VD risk. A high ABI (1.3), which indicates calcified,
oncompressible arteries, is also a marker of arterial disease.
he prevalence of PAD as indicated by an abnormal ABI
ncreases with age and is associated with traditional risk
actors for CVD (280,281).
.5.6.2. ASSOCIATION WITH INCREASED RISK
any epidemiological studies have demonstrated that an
bnormal ABI in otherwise asymptomatic individuals is
ssociated with cardiovascular events (279,282–293). A
ecent collaborative study combined data from 16 studies
279) and included a total of 24,955 men and 23,399
omen without a history of CHD. Importantly the study
ncluded data from a wide representation of the population,
ncluding blacks, American Indians, persons of Asian de-
cent, and Hispanics as well as whites (288,293–295). The
ean age in the studies ranged from 47 to 78 years, and the
RS-predicted rate of CHD ranged from 11% to 32% in
en and from 7% to 15% in women. There were 9,924
eaths (25% due to CHD or stroke) over 480 325 patient-
ears of follow-up. For an ABI of 0.9 compared with an eBI of 1.11 to 1.4, the HR for cardiovascular mortality and
ajor events was 3.33 for men and 2.71 for women (279).
hen adjusted for the FRS, the HRs were only moderately
ower (2.34 in men and 2.35 in women), demonstrating the
dditive predictive value of the ABI beyond the FRS (279).
n ABI of 1.4 was also associated with higher risk within
ost of the FRS categories. However, the greatest incre-
ental benefit of ABI for predicting risk in men was in
hose with a high FRS (20%), in whom a normal ABI
educed risk to intermediate (279). In women the greatest
enefit was in those with a low FRS (10%), in whom an
bnormally low or high ABI would reclassify them as high
isk, and in those with an intermediate FRS, who would be
eclassified as high risk with a low ABI. Reclassification
ccurred in 19% of men and 36% of women. Thus, an
bnormally low or abnormally high ABI is associated with
ncreased cardiovascular risk in both men and women, and
he risk prediction extends beyond that of the FRS alone.
.5.6.3. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
here are no randomized clinical trials that demonstrate
easurement of ABI is effective in motivating asymptom-
tic patients to comply with measures to reduce cardiovas-
ular risk. There is also no indication that serial measure-
ent of the ABI can be used to monitor treatment or guide
reatment approaches.
.5.7. Recommendation for Exercise
lectrocardiography
LASS IIb
. An exercise ECG may be considered for cardiovascular risk assess-
ment in intermediate-risk asymptomatic adults (including seden-
tary adults considering starting a vigorous exercise program), par-
ticularly when attention is paid to non-ECGmarkers such as exercise
capacity (296–298). (Level of Evidence: B)
atients who are capable of exercising on a bicycle or
readmill with a normal resting 12-lead ECG are connected
o a modified-torso 12-lead ECG and asked to exercise at
ncreasing levels of stress until exhaustion or other mile-
tones are met, such as a target heart rate or worrisome
linical findings (e.g., severe chest discomfort). Treadmill
esting is more commonly performed in the United States;
variety of protocols are used during which both speed and
rade are gradually increased in stages. Ideal exercise times
re about 8 to 12 minutes. Although the best known
easurement is change in ST-segment deviation during and
fter exercise, other important prognostic measures are
xercise capacity, chronotropic response, heart rate recovery,
nd exercise-induced arrhythmias (299).
.5.7.1. ASSOCIATION WITH INCREASED RISK AND INCREMENTAL RISK
everal specific findings on exercise testing are associ-
ted with subsequent mortality and cardiovascular events
Table 7) (299). An AHA scientific statement has described
n detail exercise test risk predictors in asymptomatic adults
299). Although many clinicians typically think of the
xercise test as primarily a measure of ST-segment changes
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Texthat may reflect ischemia, evidence has demonstrated that
he ST segment is a weak marker for prevalent and incident
AD (300,301). In contrast, non-ECG measures have
merged as stronger predictors of risk. Probably the most
owerful risk marker obtained during routine exercise test-
ng is exercise capacity; numerous investigators have consis-
ently found that depressed exercise capacity is associated
ith increased cardiovascular risk (296,298,299,302–305).
n a very large primary care population, adding exercise
ariables to clinical variables increased the C index from
.75 to 0.83 for prediction of all-cause mortality (306).
mong healthy executives, adding exercise variables to
linical variables increased the C index from 0.73 to 0.76
307).
Markers reflective of autonomic nervous system function
an predict major cardiovascular events, total mortality, and
able 7. Sample of Longitudinal Studies Reporting the Indepen
symptomatic Populations
Primary
easurement(s)
First Author
(Year, Country)
Type of
Events
Follow-Up
(y)
xercise capacity Gulati (2003, US)
(296)
All-cause
death
8.4
xercise capacity Wei (1999, US)
(298)
CVD death and
all-cause
death
10
xercise capacity
and heart rate
recovery
Adabag (2008,
US) (297)
Sudden death,
CHD death,
nonfatal
CHD, all-
cause death
7
hronotropic
response and
heart rate
recovery
Jouven (2005,
France) (310)
Sudden death 23
xercise
capacity, heart
rate recovery,
and ST-
segment
changes
Mora (2003, US)
(318)
CVD death and
all-cause
death
20
xercise
capacity, heart
rate recovery,
and ST-
segment
changes
Aktas (2004, US)
(307)
All-cause
death
8
xercise capacity Kodama (2009,
International)
(305)
All-cause
death and
CHD/CVD
events
1.1 to 26
pm indicates beats per minute; CHD, coronary heart disease; CI, confidence interval; CVD, card
etabolic equivalent; MRFIT, Multiple Risk Factor Intervention Trial; and US, United States.udden cardiac death (297,308–313). Failure of the heart date to rise appropriately during exercise has been termed
hronotropic incompetence and has been linked to adverse
utcome whether or not beta blockers are being taken
299,314,315). The fall in heart rate immediately after
xercise, also known as heart rate recovery, is thought to
eflect parasympathetic tone (316). Decreased heart rate
ecovery has been associated with death or cardiac events in
number of populations, including those that are entirely or
rimarily asymptomatic (307,309,310,313,317–319). Fre-
uent ventricular ectopy during recovery, similarly thought
o reflect abnormalities of parasympathetic nervous system
unction, are also independently associated with long-term
isk of mortality (309). The adjusted HR is 1.5 (95% CI 1.1
o 1.9; p0.003) (309).
To synthesize the clinical importance of these measures,
number of exercise test scoring schemes have been
Predictive Value of Exercise Electrocardiography Measures in
Population
haracteristics
(No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
men with
ean FRS of 6
5,721)
52 Compared with 8 METs, HR 1.9
(95% CI 1.3 to 2.9) for 5 to 8 METs
and 3.1 (95% CI 2.0 to 4.7) for
5 METs
n in preventive
edicine clinic
25,714)
44 For CVD death, HR 3.1 (95% CI 2.5 to
3.8); for all-cause death, HR 2.2
(95% CI 1.4 to 3.8); all in normal
weight; similar in overweight and
obese men
n in MRFIT
tudy (12,555)
46 For all-cause death, HR 0.85 (95% CI
0.7 to 0.9) for 8 min of Bruce
protocol compared with 6 min
HR 0.90 (95% CI 0.82 to 0.99) for
heart rate recovery 65 bpm 3 min
after exercise compared with 50 bpm
n in Paris civil
ervice (5,713)
47 For chronotropic response 89 bpm;
HR 6.18 (95% CI 2.30 to 16.11;
p0.001)
For heart rate recovery 25 bpm;
HR 2.2 (95% CI 1.02 to 4.74; p0.04)
men in LRC
revalence
tudy (2,994)
46 For CVD death, exercise capacity
below median HR 2.0 (95% CI 1.29
to 3.25); heart rate recovery below
median HR 2.9 (95% CI 1.85 to
4.39); ST-segment depression 1
mm, HR 1.0 (95% CI 0.59 to 1.80);
similar for all-cause death
n in preventive
edicine clinic
3,554)
57 For impaired exercise capacity,
HR 3.0 (95% CI 1.98 to 4.39;
p0.001); for abnormal HR
recovery 12 bpm 1 min
postexercise; HR 1.6 (95% CI 1.04
to 2.41; p0.03); not significant
for ST-segment depression
althy men and
omen in
eta-analysis
102,980)
37 to 57 For all-cause mortality, 1-MET
increase; HR 0.87 (95% CI 0.84 to
0.90); for CHD/CVD
ular disease; FRS, Framingham Risk Score; HR, hazard ratio; LRC, Lipid Research Clinics; MET,dent
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apacity, ST-segment changes, and exercise-induced angina
313,320,321). The formula for the DTS is
xercise time  (4 	 angina index)
 (5 	 maximal ST-segment depression).
he DTS has been validated in a number of populations as
redictive of risk. Of note however, the only element of the
TS that has been consistently associated with increased
isk has been exercise capacity (301,313). In both younger
nd older adults, ST-segment changes and exercise-induced
ngina have not consistently appeared as risk predictors
301,313).
The DTS has been criticized for its failure to take into
ccount demographics and simple risk factors. A nomogram
ased on simple demographics, easily obtained risk factors,
nd standard exercise test findings was found to better
iscriminate risk than the DTS (C index, 0.83 versus 0.73;
0.001); the nomogram was also successfully validated in
n external cohort (306).
.5.7.2. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
o randomized trials have specifically addressed the role of
xercise testing in these 3 areas. There is also no direct
nformation on the role of the exercise test to monitor
reatment effects in asymptomatic adults.
.5.8. Recommendation for Stress Echocardiography
LASS III: NO BENEFIT
. Stress echocardiography is not indicated for cardiovascular risk
assessment in low- or intermediate-risk asymptomatic adults. (Ex-
ercise or pharmacologic stress echocardiography is primarily used
for its role in advanced cardiac evaluation of symptoms suspected
of representing CHD and/or estimation of prognosis in patients with
known coronary artery disease or the assessment of patients with
known or suspected valvular heart disease.) (Level of Evidence: C)
.5.8.1. GENERAL DESCRIPTION
tress echocardiography can be performed with dynamic
orms of exercise, including treadmill and bicycle, as well as
ith pharmacologic stress, most often using dobutamine.
he manifestations of ischemia on echocardiography in-
lude segmental and global left ventricular dysfunction. The
se of echocardiography during treadmill testing is indicated
or those patients with an abnormal resting ECG, including
ndings of left bundle-branch block, electronically paced
hythm, and LVH, as well as for patients taking digoxin.
he diagnostic performance of the test is highly dependent
n the availability of skilled acquisition and interpretation of
he images and should be performed according to best
ractices (322). MPI with echocardiographic contrast
gents has not been widely used, and there are no currently
pproved agents available in the United States, so this
echnique is not addressed here.
The current guideline focuses on the use of tests and
rocedures that may be employed for assessment of cardio- eascular risk in the asymptomatic adult. In several sections
f this document the writing committee has also assessed
he evidence for applying conventional diagnostic testing
ith or without imaging. It is important to realize the vast
ifference in concepts between use of a diagnostic test,
sually in the symptomatic patient, to define a patient’s
ikelihood of obstructive CAD compared with stratification
f risk in an asymptomatic patient to serve as a basis for
ardiovascular preventive strategies. Stress echocardiogra-
hy is a test predominantly used in symptomatic patients to
ssist in the diagnosis of obstructive CAD. There is very
ittle information in the literature on the use of stress
chocardiography in asymptomatic individuals for the pur-
oses of cardiovascular risk assessment. Accordingly, the
lass III (LOE: C) recommendation for stress echocardi-
graphy reflects a lack of population evidence of this test for
isk assessment purposes. This contraindication to testing
ust be placed within the concept of accepted indications
or testing asymptomatic patients for diagnosis of CAD,
uch as for asymptomatic individuals undergoing preopera-
ive risk assessment (323), patients with new-onset atrial
brillation, or a clinical work-up after episodes of ventric-
lar tachycardia or syncope. In contrast, the current guide-
ine focuses on risk assessment in the asymptomatic adult,
hich must not be confused with evaluation of the patient
ithout chest pain with ischemic equivalents such as dys-
nea, where in some cases, stress testing may be considered
ppropriate. The focus of these latter evaluations is to assess
patient’s ischemic burden and the ensuing likelihood of
bstructive CAD. There are clinical practice guidelines and
ppropriate use criteria that focus on the quality of evidence
or assessment of asymptomatic patients or those with
schemic equivalents and clinical indications for the use of
tress echocardiography. The current guideline is not appli-
able in this setting of diagnosis of CAD.
.5.8.2. ASSOCIATION WITH INCREASED RISK
n a cohort of 1,832 asymptomatic adults with no history of
HD (mean age, 51 years; 51% male), the predictive value
f exercise echocardiography was examined at a mean of
lmost 5 years of follow-up (324). The incidence of signif-
cant ST-segment depression was 12%, and the incidence of
nducible wall motion abnormalities was 8%. The presence
f inducible wall motion abnormalities was not an indepen-
ent predictor of cardiac events in the entire population or
hose with 2 risk factors (324). There are additional
linical studies in patients with type 2 diabetes mellitus. One
mall series compared screening with combined exercise
lectrocardiography and dobutamine stress echocardiogra-
hy to a no-screening strategy in 141 patients with type 2
iabetes. The series found that the screening strategy was
ssociated with reduced cardiac events when those with
nducible wall motion abnormalities (21%) underwent re-
ascularization (325).
No information is currently available to assess the role of
xercise echocardiography in addition to conventional risk
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Textactors for risk assessment in asymptomatic adults. Because
f the lack of information on the role of risk assessment in
he asymptomatic adult, the writing committee thought that
here was no basis to recommend stress echocardiography
or routine risk assessment in this type of patient.
.5.8.3. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
here have been no randomized trials on exercise echocar-
iography to suggest that it can be used to motivate lifestyle
ehavior changes in asymptomatic adults. One small pilot
rial in patients with type 2 diabetes is cited above (325). No
ther trials have investigated the use of echocardiography to
uide therapy in asymptomatic adults. Thus, there is no
lear indication that an exercise echocardiogram can be used
o motivate asymptomatic adults or guide their therapy.
.5.9. Myocardial Perfusion Imaging
.5.9.1. RECOMMENDATIONS FOR MYOCARDIAL PERFUSION IMAGING
LASS IIb
. Stress MPI may be considered for advanced cardiovascular risk
assessment in asymptomatic adults with diabetes or asymptomatic
adults with a strong family history of CHD or when previous risk
assessment testing suggests high risk of CHD, such as a CAC score
of 400 or greater. (Level of Evidence: C)
LASS III: NO BENEFIT
. Stress MPI is not indicated for cardiovascular risk assessment in
low- or intermediate-risk asymptomatic adults (Exercise or pharma-
cologic stress MPI is primarily used and studied for its role in
advanced cardiac evaluation of symptoms suspected of represent-
ing CHD and/or estimation of prognosis in patients with known
CAD.) (326). (Level of Evidence: C)
.5.9.2. DESCRIPTION OF MYOCARDIAL PERFUSION IMAGING
xercise or pharmacologic stress MPI using single-photon
mission computed tomography (SPECT) or positron
mission tomography (PET) is predominantly considered
ppropriate for the clinical evaluation of symptoms sugges-
ive of myocardial ischemia or for determination of prog-
osis in patients with suspected or previously known CAD.
s noted in the stress echocardiography section, it is
mportant to recognize the distinction between the use of a
iagnostic test to define the likelihood of obstructive CAD
n a symptomatic patient and the possible role of a diag-
ostic test in risk assessment of an asymptomatic individual,
or whom the results of testing would be used in decision
aking about strategies for prevention of CVD. This
uideline is not intended to address the evaluation of
atients presenting with possible cardiovascular symptoms
r signs such as dyspnea, syncope, or arrhythmia, nor does
his guideline address the preoperative assessment of a
igh-risk patient. These patient evaluations are the topics of
ther guidelines, and the reader is referred to other guide-
ines when confronted with such symptomatic patients.
Stress myocardial perfusion SPECT and PET involve
xposure to ionizing radiation. The effective radiation dose
or SPECT and PET considerably exceeds that of a CAC
core (median effective dose: 2.3 millisievert [mSv]), and pherefore the use of these modalities should be limited to
atients in whom clinical benefit exceeds the risk of radia-
ion exposure, for example, higher-risk or older patients.
se of these procedures must be performed with the guiding
rinciple of applying effective doses that are “as low as
easonably achievable” (i.e., ALARA). The estimated effec-
ive dose for stress myocardial perfusion SPECT is 14.6
Sv, whereas that of Rb82 PET is 5 mSv (327). For all
atients, dose-reduction strategies should be used whenever
ossible (e.g., stress-only imaging), and these approaches
ay reduce SPECT doses to as low as 5 to 8 mSv (328).
he clinician is strongly urged to consider radiation expo-
ure when deciding whether the benefit of testing an
symptomatic patient outweighs the potential risks.
.5.9.3. EVIDENCE OF ASSOCIATION WITH INCREASED
ARDIOVASCULAR RISK IN ASYMPTOMATIC ADULTS
here are few studies on the role of stress MPI for risk
ssessment in asymptomatic persons. The writing commit-
ee did not identify any studies in population-based (rela-
ively unselected) asymptomatic individuals. Reported stud-
es of stress perfusion imaging in asymptomatic persons
ave involved selected higher-risk patients who were re-
erred for cardiac risk evaluation. In 1 large series of patients
eferred to a stress perfusion imaging laboratory (n3664
symptomatic patients), those with 7.5% myocardial isch-
mia had an annual event rate of 3.2%, which was consistent
ith high risk. High-risk findings were noted in 10% of
symptomatic patients who were referred. Limitations of
he study include the absence of clear indications for referral
nd absence of prior global risk assessment as a basis for
dvanced risk assessment (329). A second study, from the
ayo Clinic, selected 260 asymptomatic patients from a
uclear cardiology database (678 years, 72% male) with-
ut known CAD who were at moderate risk for CHD by
RS (330). SPECT MPI images were categorized using the
ummed stress score. Mean follow-up was nearly 10 years.
bnormal SPECT MPI scans were present in 142 patients
55%). By summed stress score categories, SPECT scans
ere low risk in 67% of patients, intermediate risk in 20%,
nd high risk in 13%. Survival was 60% for patients with
igh-risk scans (95% CI 45% to 80%), 79% with
ntermediate-risk scans (95% CI 69% to 91%), and 83%
ith low-risk scans (95% CI 77% to 88%) (p0.03),
ncluding 84% (95% CI 77% to 91%) with normal scans. In
symptomatic intermediate- to higher-risk patients, these
vailable data suggest a possible role for stress perfusion
maging in advanced risk assessment of selected asymptom-
tic patients.
Risk stratification using MPI has also been studied in
symptomatic patients with diabetes (331–337). In 1 mul-
icenter study of 370 asymptomatic persons with diabetes
ecruited from departments of diabetology (335), abnormal-
ty was defined as a fixed or reversible perfusion defect or a
ositive stress ECG. These abnormalities (compared with
atients with normal study results) were associated with a
2
p
I
D
w
m
s
f
c
l
e
t
d
t
l
i
(
A
t
t
s
o
e
a
r
m
7
t
r
s
i
p
c
s
i
a
f
(
a
(
r
o
a
a
e
O
t
(
i
t
d
p
o
t
2
T
e
h
l
P
t
c
c
d
a
c
3
r
t
b
w
2
T
s
(
s
M
a
c
p
(
s
w
t
c
n
f
c
w
a
2
2
(
C
1
C
1
C
1
2
C
e78 Greenland et al. JACC Vol. 56, No. 25, 2010
CV Risk Guideline: Full Text December 14/21, 2010:e50–103.9-fold (1.3 to 6.4) higher risk for cardiovascular events in
atients60 years of age but not for those60 years of age.
n the DIAD (Detection of Ischemia in Asymptomatic
iabetics) trial, asymptomatic, relatively low-risk patients
ith diabetes were randomized to screening for “silent”
yocardial ischemia using adenosine stress MPI as an initial
creening test versus “usual care” (337). The DIAD study
ound evidence of effective risk stratification, with annual
ardiovascular event rates of 0.4% for those with normal- or
ow-risk scans compared with 2.4% for those with a mod-
rate to large perfusion defect (p0.001) (337). However,
he overall result of the DIAD study was no significant
ifference in clinical outcomes in the screened group versus
he usual care group (see further on this point below).
Stress perfusion imaging tests have been studied in a
imited way when used as a secondary test following an
nitial evaluation with exercise ECG, carotid IMT, or CAC
333,338–343). A summary of the literature from the
SNC synthesized published reports in patients who had
hese first-level indications of higher risk. Results suggested
hat as many as 1 in 3 of higher-risk patients with a CAC
core of 400 had demonstrable ischemia. The prevalence
f ischemia can be quite high in patients with diabetes,
specially those with a family history of CHD (340,344). In
series of 510 asymptomatic patients with type 2 diabetes
ecruited from 4 London diabetes clinics, the incidence of
yocardial ischemia was 0%, 18.4%, 22.9%, 48.3%, and
1.4% for those with CAC scores of 0 to 10, 11 to 100, 101
o 400, 401 to 1000, and 1000, respectively (p0.0001).
Three studies have reported the prognosis for patients
eferred to either initial CAC screening or combined CAC
canning with stress MPI (333,341,343). In 1 series that
ncluded a mixed sample of asymptomatic patients and
atients with chest pain, high-risk CAC scores did not
onfer an elevated cardiovascular event risk. In another
eries of 621 patients who underwent hybrid PET-CT
maging with CAC scoring, one third of whom were
symptomatic, cardiovascular event-free survival was worse
or patients with ischemia on PET plus a CAC score1000
p0.001). In another study using a patient registry, data on
symptomatic patients with type 2 diabetes were reported
333). The inclusion criteria for the latter prospective
egistry included patients with diabetes who were50 years
f age with either prior carotid IMT 1.1 mm, urinary
lbumin rate 30 mg/g creatinine, or 2 of the following:
bdominal obesity, HDL cholesterol 40 mg/dL, triglyc-
rides 150 mg/dL, or hypertension 130/85 mm Hg.
ne-year event-free survival ranged from 96% to 76% for
hose with a summed stress score ranging from 4 to 14
p0.0001). These results suggest that stress perfusion
maging may have a role in the advanced testing of asymp-
omatic patients who have been evaluated with other mo-
alities and found to be at high risk of silent ischemia. Such
atients might include patients with a high-risk CAC score
f 400 or higher-risk patients with diabetes, including
hose with a strong family history of CHD. b.5.9.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY
here are limited data to demonstrate that stress-induced
vidence of silent ischemia in asymptomatic patients will
ave an impact on patient management. These data are
imited to the use of follow-up testing in the DIAD trial.
atients enrolled in the DIAD trial who were randomized
o screening with stress MPI had a higher rate of follow-up
oronary angiography and revascularization. These data are
onsistent with single-center studies that have shown that
emonstration of high-risk myocardial perfusion scans in
symptomatic patients with diabetes leads to diagnostic
ardiac catheterization to identify high-risk anatomy (e.g.,
-vessel CAD or left main CAD) with a view toward
evascularization (345,346). One nonrandomized observa-
ional study showed that asymptomatic patients with dia-
etes with high-risk stress MPI scans had a better outcome
ith revascularization than medical therapy (347).
.5.9.5. CHANGES IN PATIENT OUTCOMES
here is evidence from 1 randomized trial on the utility of
tress MPI to screen for CVD in persons with diabetes
337). The DIAD trial randomized 1,123 patients to no
creening compared with screening with adenosine stress
PI. The trial results revealed that stress MPI performed as
n initial screening test had no impact on 5-year outcomes
ompared with nonscreening or usual care of asymptomatic
atients with diabetes (337). The relative hazard was 0.88
95% CI 0.44 to 1.88) for those who were screened with
tress myocardial perfusion SPECT compared with those
ho were not screened (p0.73). Notable limitations to this
rial are its small, underpowered sample size, the high
rossover rate (n170/562 nonscreening arm undergoing
onprotocol stress testing), and the high incomplete
ollow-up rate (n81/1,123) exceeding the 49 observed
ardiovascular events. Importantly, the enrolled patients
ere low risk with an annual cardiovascular event rate of 0.6%
nd included patients with a normal resting 12-lead ECG.
.5.10. Computed Tomography for Coronary Calcium
.5.10.1. RECOMMENDATIONS FOR CALCIUM SCORING METHODS
SEE SECTION 2.6.1)
LASS IIa
. Measurement of CAC is reasonable for cardiovascular risk assess-
ment in asymptomatic adults at intermediate risk (10% to 20%
10-year risk) (18,348). (Level of Evidence: B)
LASS IIb
. Measurement of CAC may be reasonable for cardiovascular risk
assessment in persons at low to intermediate risk (6% to 10%
10-year risk) (348–350). (Level of Evidence: B)
LASS III: NO BENEFIT
. Persons at low risk (6% 10-year risk) should not undergo CAC
measurement for cardiovascular risk assessment (18,348,351).
(Level of Evidence: B)
.5.10.2. CALCIUM SCORING METHODS
ardiac CT, using either multidetector row CT or electron
eam tomography, enables the acquisition of thin slices of
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Texthe heart and coronary arteries gated to diastole to minimize
oronary motion. Both are sensitive noninvasive techniques
hat can detect and quantify coronary calcium, a marker of
therosclerosis (352,353). The test is typically performed in
prospectively ECG-triggered scanning mode with 2.5- to
.0-mm thick axial images obtained through the heart. The
uantity of calcium within the coronary arteries is typically
cored as the area affected on the scan, multiplied by a
eighting factor depending on the Hounsfield unit density
f the calcium deposits (352). The radiation dose in a
rospectively triggered acquisition is low, with a typical
ffective dose of 1.5 mSv (354). Due to the radiation
xposure and general low prevalence of calcification in men
40 years of age and women 50 years of age, patient
election is an important consideration. CT scanning should
enerally not be done in men 40 years old and women
50 years old due to the very low prevalence of detectable
alcium in these age groups.
The widespread use of CCTA has also raised concerns
bout radiation dose for patients. The National Council on
adiation Protection Report No. 160 stated that radiation
xposure to the U.S. population due to medical sources
ncreased 7 times between 1986 and 2006 (355). CT
alcium scoring produces the same amount of radiation as 1
o 2 mammograms performed on each breast (356). The
adiation dose in a prospectively triggered acquisition is low,
ith a typical effective dose of 0.9 to 1.1 mSv (354,357), but
oses can be higher if retrospective imaging is used (358).
ll current recommendations suggest prospective triggering
e used for CAC scoring. CT personnel must be constantly
ware of the risks of radiation and strive to apply the lowest
ose to the patient consistent with the clinical study.
ecause of radiation exposure and the general low preva-
ence of calcification in men 40 years of age and women
50 years of age, CT scanning should generally not be done
n these younger-age patients.
.5.10.3. DATA ON INDEPENDENT RELATIONSHIP TO
ARDIOVASCULAR EVENTS
he majority of published studies have reported that the
otal amount of coronary calcium (usually expressed as the
gatston score) provides information about future CAD
vents over and above the information provided by standard
isk factors. Intermediate-risk patients with an elevated
AC score (intermediate FRS and CAC300) had a 2.8%
nnual rate of cardiac death or MI (roughly equivalent to a
0-year rate of 28%) that would be considered high risk
352). Pooled data from 6 studies of 27,622 asymptomatic
atients were summarized in an ACCF/AHA clinical ex-
ert consensus document that examined predictors of the
95 CHD deaths or MIs (359). The 11,815 subjects who
ad CAC scores of 0 had a low rate of events over the
ubsequent 3 to 5 years (0.4%, based on 49 events).
ompared with a CAC score of 0, a CAC score between
00 and 400 indicated a RR of 4.3 (95% CI 3.5 to 5.2;
0.0001), a score of 400 to 1000 indicated a RR of 7.2 t95% CI 5.2 to 9.9; p0.0001), and a score 1000
ndicated a RR of 10.8 (95% CI 4.2 to 27.7; p0.0001).
he corresponding pooled rates of 3- to 5-year CHD death
r MI rates were 4.6% (for scores from 400 to 1000) and
.1% (for scores1000), resulting in a RR ratio of 7.2 (95%
I 5.2 to 9.9; p0.001) and 10.8 (95% CI 4.2 to 27.7;
0.0001).
Since the ACCF/AHA expert consensus document was
ublished, other prospective confirmatory studies have been
ublished (18,348,351,353,354). These studies have dem-
nstrated that the relationships between CAC outcomes are
imilar in men and women and different ethnic groups
353,354). Each of these studies demonstrated that the
UC to predict coronary artery events is significantly higher
ith CAC than either Framingham or PROCAM (Mün-
ter Heart Study) risk stratification alone. In MESA, the C
tatistic with traditional risk factors was 0.79 for major
oronary events in the risk factor prediction model and 0.83
n the risk factor plus CAC model (p0.006) (18).
.5.10.4. USEFULNESS IN MOTIVATING PATIENTS
o understand the clinical utility of CAC testing as a risk
ssessment tool, it is imperative to demonstrate that it alters
linical management (such as the use of preventive medica-
ions). In an observational survey study, Kalia et al. showed
hat self-reported lipid-lowering medication provision in-
reased from 44% over 3 years to 90% in those with
aseline calcium scores in the top 75th percentile for age
nd sex (p0.001) (360). This finding was independent of
nderlying cardiovascular risk factors, age, and sex. Other
ardiovascular risk behaviors were reported to be beneficially
ffected, specifically showing that higher baseline CAC was
trongly associated with initiation of aspirin therapy, dietary
hanges, and increased exercise (361).
A randomized controlled study suggested that although a
alcium scan did not in itself improve net population
ealthy behaviors, the post-test recurring interactions with a
ealthcare provider can be useful to reinforce lifestyle and
reatment recommendations that could ensue from calcium
esting (362).
.5.10.5. USE AS A REPEAT MEASURE TO MONITOR EFFECTS OF THERAPY IN
SYMPTOMATIC PERSONS
oronary calcium progresses at typically 10% to 20% of the
aseline value per year, and among persons 45 years of
ge, approximately 7% per year of those without calcium
evelop detectable coronary calcium. The value of repeat
alcium scanning is governed by the interscan interval, rate
f coronary calcium progression, variability in repeated
easurements, and independent association to shifts in
rognosis and management based on the observed calcium
rogression rate. Although preliminary data suggest that a
alcium scan progression rate of15% per year is associated
ith a 17-fold increased risk for incident CHD events
363), there are no data demonstrating that serial CAC
esting leads to improved outcomes or changes in therapeu-
ic decision making (354).
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UIDING THERAPY
alcium scores 100 to 300 are associated with a high rate
f incident CHD events over the ensuing 3 to 5 years, so
hat persons with calcium scores in this range are a suitable
arget group for stringent lifestyle recommendations, selec-
ion of evidence-based therapeutic agents to reduce cardio-
ascular risk, and focus on adherence to medical recommen-
ations. In the Prospective Army Coronary Calcium study,
mong 1640 participants followed up for 6 years, use of
tatin and aspirin was independently 3.5- and 3-fold greater
n those with any coronary calcium over 6 years, suggesting
anagement changes can occur following calcium screening
n community-based cohorts (364). Multiple logistic regres-
ion analysis, controlling for National Cholesterol Educa-
ion Program (NCEP) risk variables, showed that CAC was
ndependently associated with a significantly higher likeli-
ood of use of statin, aspirin, or both (OR 6.97; 95% CI
.81 to 10.10; p0.001) (364). The OR for aspirin and
tatin use based on NCEP risk factors alone was dramati-
ally lower (OR 1.52; 95% CI 1.27 to 1.82; p0.001).
ecent data from MESA suggest similar effects of CAC
isualization on lipid-lowering and aspirin therapy (365).
.5.10.7. EVIDENCE FOR IMPROVED NET HEALTH OUTCOMES
vidence is not available to show that risk assessment using
AC scoring improves clinical outcomes by reducing mor-
ality or morbidity from CAD.
.5.10.8. SPECIAL CONSIDERATIONS
.5.10.8.1. CORONARY CALCIUM SCORING IN WOMEN. A vast
ajority of women75 years of age are classified by FRS to
e low risk. In 1 study of 2,447 consecutive asymptomatic
omen without diabetes (5510 years), 90% were classified
s low risk by FRS (9%), 10% as intermediate risk (10% to
0%), and none had a high-risk FRS 20% (366). CAC
as observed in 33%, whereas moderate (CAC 100), a
arker of high risk, was seen in 10% of women. Overall,
0% of women had CAC 75th percentile for age and
ender, another marker for future CHD events. However,
hen FRS was used, the majority (84%) of these women
ith significant subclinical atherosclerosis 75th percentile
ere classified as low risk, whereas only 16% were consid-
red intermediate risk. Thus, FRS frequently classifies
omen as being low risk, even in the presence of significant
AC. Based on this 1 substudy from MESA, it is possible
hat CAC scoring may provide incremental value to FRS in
dentifying which asymptomatic women may benefit from
argeted preventive measures (349). A recent report noted
et reclassification improvement with CAC in relation to
isk factors for all-cause mortality in women 60 years of
ge (367). In terms of the overall predictive capacity of high
alcium scores, several studies have demonstrated that
AC-associated outcomes are similar in men and women
368,369).
For a discussion of the utility of CAC testing in personsith diabetes, see Section 2.6.1. t.5.10.8.2. COMPARISON OF CORONARY ARTERY CALCIUM
CORING WITH OTHER RISK ASSESSMENT MODALITIES. Sev-
ral studies have compared multiple techniques for cardio-
ascular risk stratification (350,369–371). Four studies
omparing the predictive abilities of hsCRP with CAC have
emonstrated that CAC remains an independent predictor
f cardiovascular events in multivariable models, whereas
RP no longer retains a significant association with inci-
ent CHD (350,369–371). This has recently been con-
rmed in MESA as well (18,351). The CAC score was also
hown to be a better predictor of subsequent CVD events
han carotid IMT. Multivariable analysis revealed HRs for
HD of 1.7 (95% CI 1.1 to 2.7; p0.07) for carotid IMT
nd 8.2 (95% CI 4.5 to 15.1; p0.001) for CAC score
quartile 4 versus quartiles 1 and 2) (252).
.5.11. Coronary Computed Tomography Angiography
.5.11.1. RECOMMENDATION FOR CORONARY COMPUTED
OMOGRAPHY ANGIOGRAPHY
LASS III: NO BENEFIT
. Coronary computed tomography angiography is not recommended
for cardiovascular risk assessment in asymptomatic adults (372).
(Level of Evidence: C)
.5.11.2. GENERAL DESCRIPTION
CTA has been widely available since around 2004, when
4-detector scanners were produced by multiple vendors.
wo basic scanning protocols may be used; both require
CG monitoring and gating. Helical (or spiral) scanning
ses continuous image acquisition while the patient moves
lowly through the scanner plane. Axial scanning incorpo-
ates a scanning period, followed by a patient movement
eriod, followed by another scanning period (step-and-
hoot). Compared with invasive coronary angiography using
cine system, both the temporal and spatial resolution of
CTA are far less (spatial: 200 microns versus 400; tem-
oral: 10 ms versus approximately 80 to 190 ms, depending
n the type of scanner). CCTA provides the best quality
mages when the heart rate is regular and slow (60 bpm if
ossible).
CCTA has been compared with invasive coronary an-
iography for detection of atherosclerosis (typically defined
s a 50% diameter stenosis) (373). Sensitivities and speci-
cities from 40 studies are consistently in the range of
5% to 95%, and the most important test feature is the high
egative predictive value (98%) (373). In addition, CCTA
an image mild plaque (50%) in the vessel wall. Plaques
ay be roughly characterized according to their density
Hounsfield units) as calcified or noncalcified. CCTA re-
uires a CT scanner with at least 64 detector rows and
pecialized software (approximate cost, $1 million). Con-
ern has been raised that CCTA uses ionizing radiation.
CTA studies using unmodulated, helical scanning deliver
2 to 24 mSv of radiation per examination (373). Methods
o reduce the radiation dose, including ECG dose modula-
ion or prospective ECG-triggered axial scanning, have
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estimated radiation dose associated with CCTA) (374).
.5.11.3. ASSOCIATION WITH INCREASED RISK AND INCREMENTAL
REDICTION IN ASYMPTOMATIC PERSONS
ery limited information is available on the role of CCTA
or risk assessment in asymptomatic persons. In a study
rom Korea, 1,000 middle-aged patients underwent CCTA
s a component of a general health evaluation (372).
atients were either self-referred to this examination or
eferred by a physician. Patients with chest discomfort or
nown CAD were excluded from the analysis. Clinical
ollow-up was obtained at 172 months in 97% of
atients. Coronary calcium was detected in 18% of patients,
nd 22% had identifiable atherosclerotic plaque. Significant
50%) stenoses were found in 5% of patients. CCTA
esults were compared with the NCEP ATP III risk
lassification. The majority of patients were classified as low
isk (55.7%) by NCEP criteria. Only 10.2% were classified
s high risk. The prevalence of significant coronary stenoses
n the low-, moderate- and high-risk groups was 2%, 7%,
nd 16%, respectively. During follow-up, 15 patients had
cardiac events,” although 14 of these were revascularization
rocedures prompted by the CCTA results. There were no
eaths or MIs. Additional diagnostic testing was performed
n 14% of patients identified as having coronary atheroscle-
osis, representing 3.1% of the entire screened population.
n the basis of the small number of nonprocedural events in
his study, the authors could not compare CCTA results
ith the NCEP risk assessment data for risk prediction
urposes. No other studies have been reported to date on
he potential utility of CCTA results for risk assessment in
symptomatic adults with coronary events as the outcome.
.5.11.4. CHANGES IN PATIENT OUTCOMES
here are no published trials evaluating the impact of
pecific therapy on clinical outcome in patients identified as
aving noncalcified atheroma by CCTA.
.5.12. Magnetic Resonance Imaging of Plaque
.5.12.1. RECOMMENDATION FOR MAGNETIC RESONANCE IMAGING
F PLAQUE
LASS III: NO BENEFIT
. MRI for detection of vascular plaque is not recommended for
cardiovascular risk assessment in asymptomatic adults. (Level of
Evidence: C)
.5.12.2. GENERAL DESCRIPTION
RI is a noninvasive method of plaque measurement that
oes not involve ionizing radiation. Studies of the aorta and
he femoral and carotid arteries have demonstrated the
apability of MRI for detection and quantification of
therosclerosis and suggested its potential for risk assess-
ent and evaluation of the response to treatment in asymp-
omatic patients. MRI seems to offer the greatest role for
laque characterization as distinct from lesion quantifica-
ion. Examination of plaque under different contrast leighting (black blood: T1, T2, proton density-weightings,
nd magnetization prepared rapid gradient echocardiogra-
hy or bright blood: time of flight) allows characterization
f individual plaque components (375,376), including lipid-
ich necrotic core (377), fibrous cap status (378), hemor-
hage (379,380), and calcification (377,381,382). Although
ost magnetic resonance plaque imaging studies do not
equire exogenous contrast administration, gadolinium-
ased contrast agents can further improve delineation of
ndividual plaque components such as the fibrous cap and
ipid-rich necrotic core (383,384).
Several studies have demonstrated that MRI findings are
orrelated with atherosclerosis risk factors. Aortic MRI
canning in 318 patients participating in the Framingham
eart Study found that after age adjustment, plaque prev-
lence and burden correlated with FRS for both women and
en (385). In another Framingham Heart Study, subclin-
cal aortic atherosclerosis was seen in nearly half of subjects
nd increased with advancing age. Hypertension was asso-
iated with increased aortic plaque burden. In the MESA
tudy, aortic wall thickness measured with MRI increased
ith age, but males and blacks had the greatest wall
hickness (386). In another MESA study, it was found that
hickened carotid walls and plasma total cholesterol, but not
ther established CHD risk factors, were strongly associated
ith lipid core presence by MRI (387).
A few small prospective studies have been done to
nvestigate characteristics of carotid artery plaque on MRI
hat are associated with disease progression and future
ardiovascular events. One study examined patients with
ymptomatic and asymptomatic carotid disease to determine
hether fibrous cap thinning or rupture as identified on
RI were associated with a history of recent transient
schemic attack or stroke. When compared with patients
ith a thick fibrous cap, patients with a ruptured cap were
3 times more likely to have had a recent transient ischemic
ttack or stroke (388). In a separate study of symptomatic
arotid disease, patients with lipid cores in carotid plaque by
RI had ipsilateral cerebral infarctions more often than
hose without lipid cores (68% versus 31%; p0.03) (389).
nother study performed carotid MRI on 53 patients
ithin 7 days of a second cerebrovascular accident. Patients
ith “vulnerable” carotid lesions, as defined by eccentric
hape and heterogeneous signal on MRI, had an 8 times
reater risk of a third cerebrovascular accident compared
ith those without vulnerable lesions (24% versus 3%;
0.023) (390).
Prospective studies demonstrated that hemorrhage within
arotid atherosclerotic plaques was associated with an accel-
rated increase in subsequent plaque volume over a period of
8 months (391). An increased risk of ipsilateral cerebro-
ascular events has also been reported over a mean follow-up
eriod of 38.2 months in asymptomatic patients who had
0% to 79% carotid stenosis and the presence of a thin or
uptured fibrous cap, intraplaque hemorrhage, or a larger
ipid-rich necrotic core (392). These studies support the
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otent atherogenic stimulus.
At this time there are no published prospective popula-
ion data to evaluate the role of MRI findings in risk
ssessment of asymptomatic adults. A number of large-scale
tudies are ongoing. It is recommended that additional
arge-scale multicenter trials be conducted to evaluate the
ossibility of using MRI in the detection of atherosclerosis
n asymptomatic patients.
Rapid technological progress is transforming the imaging
f atherosclerotic CVD at the molecular level using nano-
articles (393). In addition, a new generation of hybrid
echnology is now becoming available; this technology
ombines multiple imaging modalities, including PET in a
ingle platform (e.g., PET/CT and MR/PET), using 1
achine for 1 type of imaging to measure atherosclerotic
laque metabolic activity with anatomical special resolution
nd contrast (394–396). There is no information available
et on the role of these newer tests for risk assessment in the
symptomatic adult.
.6. Special Circumstances and Other Considerations
.6.1. Diabetes Mellitus
.6.1.1. RECOMMENDATIONS FOR PATIENTS WITH DIABETES
LASS IIa
. In asymptomatic adults with diabetes, 40 years of age and older,
measurement of CAC is reasonable for cardiovascular risk assess-
ment (344,397–399). (Level of Evidence: B)
LASS IIb
. Measurement of HbA1C may be considered for cardiovascular risk
assessment in asymptomatic adults with diabetes (400). (Level of
Evidence: B)
. Stress MPI may be considered for advanced cardiovascular risk
assessment in asymptomatic adults with diabetes or when previous
risk assessment testing suggests a high risk of CHD, such as a CAC
score of 400 or greater. (Level of Evidence: C)
.6.1.2. GENERAL DESCRIPTION AND BACKGROUND
VD is the major cause of morbidity, mortality, and
ealthcare costs for patients with diabetes (401). Compared
ith the general population, patients with diabetes have a 4
imes greater incidence of CHD (402) and a 2- to 4-fold
igher risk of a cardiovascular event (307). The risk of MI
n patients with diabetes without prior documented CHD is
imilar to the risk of reinfarction in patients without
iabetes with known CHD (403). Women with type 2
iabetes are particularly prone to developing cardiovascular
omplications (the age-adjusted risk ratio of developing
linical CHD among people with diabetes was 2.4 in men
nd 5.1 in women compared with patients without diabetes)
403).
The prevalence of significant coronary atherosclerosis in a
ruly representative population of patients with type 2
iabetes has not been ascertained. One estimate is that 20%
f patients with diabetes have coronary atherosclerosis
404). However, in an asymptomatic and uncomplicated 8ohort of patients with type 2 diabetes, 46.3% had evidence
f coronary artery calcification reflective of coronary athero-
clerosis (344). The prevalence of CAD on multislice CT
as 80% in a group of 70 asymptomatic patients with type
diabetes (399). The majority of these patients had diffuse
nvolvement of all 3 coronary arteries. In another study by
his group, 60% of asymptomatic patients with diabetes had
vidence of coronary calcification, of which 18% had cal-
ium scores of 400 (405). Seventy percent had coronary
uminal narrowing of 1 or more coronary arteries on
ultislice CT coronary angiography, patients with diabetes
howed more plaques on multislice CT than patients
ithout diabetes (7.13.2 versus 4.93.2; p0.01) with
ore calcified plaques (52% versus 24%) (406). On invasive
rayscale intravascular ultrasound, patients with diabetes in
his study had a larger plaque burden (48.7%10.7% versus
0.0%12.1%; p0.03). Asymptomatic patients with dia-
etes have more coronary calcification than patients without
iabetes even when controlling for other variables (407–409),
nd for every increase in CAC on CT scanning, mortality
or patients with diabetes is higher than in patients without
iabetes (407). However, patients with diabetes with no
oronary calcium have a survival rate similar to that of
ubjects without diabetes and with no identifiable coronary
alcium (407). The overall rate of death or MI was 0%,
.6%, 13.3%, and 17.9% (p0.0001) in patients with
iabetes with a CAC score of 100, 100 to 400, 401 to
000 and 1000, respectively (344). ROC curve analysis
howed by AUC that the CAC (AUC: 0.92; 95% CI 0.87
o 0.96) was superior to the UKPDS (United Kingdom
rospective Diabetes Study Risk Score) (AUC, 0.74; 95%
I 0.65 to 0.83) and FRS (AUC, 0.60; 95% CI 0.48 to 0.73;
0.0001) for predicting cardiac events, with a risk ratio of
0.1 (95% CI 1.68 to 61.12) for patients with a score of 100
o 400 and 58.1 (95% CI 12.28 to 100) for scores 1000
344).
The CAC score has been found to be predictive beyond
onventional risk factors in several studies in patients with
iabetes. In the PREDICT (Patients with Renal Impair-
ent and Diabetes Undergoing Computed Tomography)
tudy, 589 patients with type 2 diabetes underwent CAC
easurement (398). At a median of 4 years’ follow-up, in a
redictive model that included CAC score and traditional
isk factors, the CAC score was a highly significant inde-
endent predictor of CHD events or stroke. The model
ound that a doubling in calcium score was associated with
32% increase in risk of events (29% after adjustment).
nly the homeostasis model assessment of insulin resistance
redicted primary endpoints independent of the CAC
core. In another study, after adjusting for CHD risk
actors, the CAC score was significantly associated with
ccurrence of coronary events in patients without diabetes
ut not in patients with diabetes (410). Another study
erformed CAC measurement in 716 asymptomatic pa-
ients with diabetes and no history of CHD (397). During
years of follow-up, 40 patients had MI and 36 additional
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ignificantly higher in those with events compared with
hose without events, 5.6% per year for patients with scores
f 400 versus 0.7% per year for those with lower scores
397). The area under the ROC curve with CAC in the
odel was significantly higher (0.77) for prediction of MI
han the FRS (0.63).
.6.1.3. ELECTROCARDIOGRAPHIC STRESS TESTING FOR SILENT
YOCARDIAL ISCHEMIA (SEE SECTION 2.5.7)
he value of exercise ECG testing to detect silent ischemia
nd assess prognosis has been evaluated in a few small
tudies of asymptomatic patients with diabetes (411–416).
CG stress testing has an approximate 50% sensitivity and
0% specificity (401). The positive predictive value for
etecting CAD using coronary angiography as the gold
tandard ranges between 60% and 94% and was higher in
en than women (401,416). Recommendations for exercise
tress testing for risk assessment do not appear to be
ifferent in patients with diabetes and patients without
iabetes.
.6.1.4. NONINVASIVE STRESS IMAGING FOR DETECTION OF ISCHEMIA
ND RISK STRATIFICATION (SEE SECTION 2.5.9)
he prevalence of asymptomatic ischemia as determined by
oninvasive imaging in patients with diabetes ranges from
6% to 59% (345,346,417–419) and depends on the pretest
linical risk of CAD in the population. The DIAD study
337) was composed of a group of patients with type 2
iabetes who were at lower risk than those undergoing stress
maging in other studies, with only 6% of the 522 patients
anifesting large defects on adenosine MPI. All had a
ormal resting ECG, whereas in a separate Mayo Clinic
ohort, 43% had abnormal Q waves on the ECG and 28%
ad peripheral vascular disease (346). Approximately 50% of
he Mayo Clinic study patients were referred for preopera-
ive testing for risk assessment. In another report from the
ame group, 58.6% of asymptomatic patients with diabetes
ad an abnormal scan, and 19.7% had a high-risk scan
345). In another retrospective study, 39% of asymptomatic
atients with diabetes had an abnormal stress scan (419). Of
hose presenting with dyspnea, 51% had an abnormal
erfusion study. The annual hard event rate at follow-up
7.7%) was highest in those presenting with dyspnea com-
ared with 3.2% in those presenting with angina. Using
ontrast dipyridamole echocardiography, approximately
0% of asymptomatic patients with diabetes who were 60
ears of age had abnormal myocardial perfusion with vaso-
ilator stress.
Asymptomatic patients with diabetes who have high
AC scores have a high prevalence of inducible ischemia on
tress imaging (339). In a prospective study, 48% of patients
ith diabetes with a CAC score of 400 had silent
schemia on SPECT imaging, and in those with a score of
1000, 71.4% had inducible ischemia (344). The majority
f the defects were moderate to severe. Patients with
iabetes with inducible ischemia have a higher annual death sr nonfatal infarction rate compared with patients without
iabetes with similar perfusion abnormalities on stress
maging (10% versus 6%) (420). Also, the greater the degree
f ischemia, the worse the outcome during follow-up in
oth asymptomatic and symptomatic patients with diabetes
344,421). The risk ratio for cardiac events was 12.27 (95%
I 3.44 to 43.71; p0.001) for patients with5% ischemic
urden on stress SPECT (344). These observations should
e tempered by the recent report that 16% of patients with
o coronary calcium had inducible ischemia by rest-stress
ubidium-82 PET imaging (343). The prevalence of diabe-
es was 28% in that study. These data, in aggregate, suggest
hat coronary calcium measurement in patients with diabe-
es may justify different approaches to risk assessment
ompared with patients without diabetes. The writing
ommittee therefore judged it reasonable to perform coro-
ary calcium measurement for cardiovascular risk assess-
ent in asymptomatic patients with diabetes who were40
ears of age.
.6.1.5. USEFULNESS IN MOTIVATING PATIENTS
o date there is no evidence that performing coronary
alcium imaging by CT scanning is effective in motivating
atients to better adhere to lifestyle changes, medical
herapy of diabetes, or primary prevention measures to
educe the risk of developing coronary atherosclerosis or
uture ischemic events.
.6.1.6. EVIDENCE OF VALUE FOR RISK ASSESSMENT FOR CORONARY
THEROSCLEROSIS OR ISCHEMIA OR BOTH TO GUIDE TREATMENT OR
HANGE PATIENT OUTCOMES
ecause of the high risks associated with diabetes, diabetes
as been designated as a CHD risk equivalent by the NCEP
27). One study randomized 141 patients with type 2
iabetes without known CAD to receive exercise ECG/
ipyridamole stress echocardiographic imaging or a control
rm (325). If a test result was abnormal, coronary angiog-
aphy was performed with subsequent revascularization as
ndicated by anatomic findings. At a mean follow-up of 53.5
onths, 1 major event (MI) and 3 minor events (angina)
ccurred in the testing arm, and 11 major and 4 minor
vents occurred in the control arm. Numbers in the study
ere too small to be considered definitive. In the DIAD
tudy, 561 low-risk asymptomatic patients were randomized
o screening with adenosine SPECT perfusion imaging; 562
atients were randomized to no testing (337). All patients
ad a normal resting ECG and no prior history of CAD.
ver a mean follow-up of 4.8 years, the cumulative event
ate was 2.9% (0.6% per year), and there was no difference
n event rates between the 2 groups. In the tested group,
hose with moderate or large defects had a higher cardiac
vent rate than those with a normal scan or small defects
337).
.6.1.7. DIABETES AND HEMOGLOBIN A1C
bA1C is used to integrate average glycemic control over
everal months and predict new-onset diabetes (156). A
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ffective to screen for the presence of diabetes (157). Some
xperts have noted that screening with HbA1C might be
dvantageous because it can be performed in nonfasting
ndividuals (422). The ADA now endorses the use of
bA1C to diagnose diabetes and assess for future risk of
iabetes in higher-risk patients (158,423).
.6.1.8. ASSOCIATION WITH CARDIOVASCULAR RISK
igher HbA1C concentrations have been associated with
levated risk of CVD in asymptomatic persons with diabetes
154). In a meta-analysis by Selvin et al., adjusted RR
stimates for glycosylated hemoglobin (total glycosylated
emoglobin, hemoglobin A1, or HbA1C levels) and CVD
vents (CHD and stroke) were pooled by using random-
ffects models (154). Three studies involved persons with
ype 1 diabetes (n1688), and 10 studies involved persons
ith type 2 diabetes (n7435). The pooled RR for CVD
as 1.18; this represented a 1% higher glycosylated hemo-
lobin level (95% CI 1.10 to 1.26) in persons with type 2
iabetes. The results in persons with type 1 diabetes were
imilar but had a wider CI (pooled RR 1.15 [95% CI 0.92
o 1.43]). Important concerns about the published studies
ncluded residual confounding, the possibility of publication
ias, the small number of studies, and the heterogeneity of
tudy results. The authors concluded that, pending confir-
ation from large, ongoing clinical trials, this analysis
uggests that chronic hyperglycemia is associated with an
ncreased risk for CVD in persons with diabetes.
.6.1.9. USEFULNESS IN MOTIVATING PATIENTS, GUIDING THERAPY, AND
MPROVING OUTCOMES
t is unknown whether knowledge of HbA1C is associated
ith better cardiovascular clinical outcomes in asymptom-
tic patients with diabetes. In persons with established
iabetes, knowledge of HbA1C concentration was associ-
ted with better understanding of diabetes care and glucose
ontrol (424). However, such knowledge was unaccompa-
ied by objective evidence of better clinical outcomes (424).
t is unknown whether HbA1C is useful for motivating
ersons without diabetes.
Although the beneficial effects of glycemic control for
icrovascular complications have been demonstrated by
umerous studies, the benefits for macrovascular complica-
ions, particularly CVD, remain controversial (425–427).
revention trials have demonstrated that persons with
mpaired glucose tolerance have less progression to overt
iabetes with lifestyle and pharmacologic interventions but
ithout accompanying reductions in CVD complications
428). A meta-analysis of randomized controlled trials of
ersons with diabetes reported that improved glycemic
ontrol was associated with an improved IRR for macrovas-
ular complications—mainly CVD—for both type 1 (IRR
.38, 95% CI 0.26 to 0.56) and type 2 (IRR 0.81, 95% CI
.73 to 0.91) diabetes (429). However, the meta-analysis
id not demonstrate a reduction in cardiac events in persons
ith type 2 diabetes (IRR 0.91, 95% CI 0.80 to 1.03) (429). eRecent large, randomized, controlled studies have also
ailed to demonstrate that intensive blood glucose control
nd a lower HbA1C level is accompanied by a reduction in
acrovascular events (430–432).
.6.2. Special Considerations: Women
he rationale for providing a separate section for risk
ssessment considerations in women was based on reports of
nderrepresentation of females within the published litera-
ure and clinicians who considered women at lower risk
hen their profiles were comparable to those of men.
oreover, the focus on special considerations in testing
omen has been put forward as a result of frequent
eporting of underutilization of diagnostic and preventive
ervices and undertreatment in women with known disease
433).
.6.2.1. RECOMMENDATIONS FOR SPECIAL CONSIDERATIONS IN WOMEN
LASS I
. A global risk score should be obtained in all asymptomatic women
(22,434). (Level of Evidence: B)
. Family history of CVD should be obtained for cardiovascular risk
assessment in all asymptomatic women (22,55). (Level of Evidence: B)
.6.2.2. DETECTION OF WOMEN AT HIGH RISK USING TRADITIONAL RISK
ACTORS AND SCORES
early 80% of women 18 years of age have 1 or more
raditional CHD risk factors (435). Diabetes and hypertri-
lyceridemia are associated with increases in CHD mortal-
ty in women more so than in men (436,437). In women,
raditional and novel risk factors are prevalent and fre-
uently cluster (i.e., metabolic syndrome) (438–440). CHD
isk accelerates greatly for women with multiple risk factors,
nd CHD risk notably increases after menopause.
Global risk scores, such as the FRS, classify the majority
f women (90%) as low risk, with few assigned to
igh-risk status before the age of 70 years (434,441). Several
eports have examined the prevalence of subclinical athero-
clerosis in female FRS subsets (349,366). In a recent study
f 2447 women without diabetes, 84% with significant
oronary artery calcification (75th percentile) were classi-
ed with a low FRS (366). The lack of sensitivity of FRS
stimates in women was presented in several reports, sug-
esting lower utility of FRS in female patients (366,441).
he Reynolds risk score in women improved risk reclassi-
cation when compared with the FRS by including hsCRP,
bA1C (if the patient has diabetes), and family history of
remature CHD (22). This finding has not been uniformly
onfirmed in other studies that included women.
.6.2.3. COMPARABLE EVIDENCE BASE FOR RISK STRATIFICATION
F WOMEN AND MEN
ithin the past decade, high-quality, gender-specific evi-
ence in CHD risk stratification of women has emerged for
ovel risk markers (e.g., hsCRP) and cardiovascular imaging
odalities (e.g., carotid IMT, CAC). This evidence revealsffective and, importantly, similar risk stratification for
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December 14/21, 2010:e50–103 CV Risk Guideline: Full Textomen and men as based on relatively large female cohorts
r a sizeable representation of females. Detailed discussions
nd recommendations for each of the tests are provided in
ections 2.4.2 for hsCRP, 2.5.1 for resting ECG, 2.5.3 for
arotid IMT, 2.5.6 for ABI, 2.5.7 for exercise ECG, and
.5.10 for CAC. In the case of hsCRP, carotid IMT, ABI,
AC, resting ECG, and exercise ECG, the recommenda-
ions for men apply similarly to women. Limited female-
pecific evidence is also available for FMD, thus warranting
Class III, LOE B recommendation similar to that for
en.
.6.3. Ethnicity and Race
variety of disparities exist in different ethnic groups with
espect to cardiovascular risk factors, incidence, and out-
omes (442). In 2002, age-adjusted death rates for diseases
f the heart were 30% higher among African Americans
han among whites of both sexes. Disparities were also
ommon with respect to the presence of atherosclerotic risk
actors, with Hispanics and black women demonstrating the
ighest rates of obesity. Blacks also had the highest rates for
ypertension, whereas hypercholesterolemia was highest
mong white and Mexican-American males and white
omen. Lower educational level and socioeconomic status
onferred a greater risk of dying from heart disease in all
thnic groups (443).
Minimal information is available at this time with regard to
iffering risk assessment strategies in ethnic groups other than
hites. The writing committee did not find evidence to suggest
hat ethnic groups other than whites should undergo selective
isk assessment approaches based on ethnicity.
.6.4. Older Adults
lthough increasing age is a risk factor for CVD, with
rogression of age, the prevalence of traditional risk factors
lso rises. Conceptually, risk intervention could be antici-
ated to have greater benefit at an elderly age, due to the
ncreased absolute risk for coronary events; however, age
omparisons for risk interventions have not been rigorously
ested. Furthermore, the term “elderly” is used to describe a
ange of age subgroups from 65 to 74, 75 to 84, and 85
ears in different studies. Elderly patients in the community
lso vary substantially from those in clinical trials, with
reater comorbidity, renal dysfunction, traditional risk fac-
ors, etc., and with very limited data available for the oldest
f the old.
In the Cardiovascular Health Study, subclinical markers
increased carotid IMT, decreased ABI, ECG, history of
I, echocardiographic left ventricular dysfunction, coro-
ary calcium) predicted CVD events more than traditional
isk scores. The DTS does not predict cardiac survival
eyond age 75, with a 7-year cardiac survival for those
lassified as low, intermediate, and high risk being 86%,
5%, and 69%, respectively (444). Elderly patients have a
ore adverse prognosis than younger patients with the same
uke risk score. Based on information drawn largely from ahe Cardiovascular Health Study, application of traditional
isk factors for risk assessment in the elderly, as well as
elected other tests, can be considered an evidence-based
pproach.
.6.5. Chronic Kidney Disease
hronic kidney disease, the permanent loss of kidney
unction, is considered a coronary risk equivalent in various
bservational studies. However, data are insufficient to
efine differences in outcomes in populations with different
egrees of renal insufficiency versus normal renal function.
ata for lipid lowering with statins in the TNT (Treating to
ew Targets) study, a population with documented CAD,
uggest serial improvement in renal function and clinical
utcome, but extrapolation to an asymptomatic healthy
opulation is inappropriate (445). Lipid lowering restricted
o the elderly in the PROSPER (Prospective Study of
ravastatin in the Elderly at Risk) study failed to show
enefit. Similarly, lipid lowering in a dialysis population
ailed to show benefit (446). In TNT, patients with diabetes
ith mild to moderate chronic kidney disease demonstrated
arked reduction in cardiovascular events with intensive
ipid lowering in contrast to previous observations in pa-
ients with diabetes with end-stage renal disease. It is
mportant to note that TNT was not a study of asymptom-
tic adults (the focus of this guideline) but rather was
ocused on a CAD population.
. Future Research Needs
.1. Timing and Frequency of Follow-Up for
eneral Risk Assessment
here is little information available in the research literature
o suggest the optimal timing to initiate risk assessment in
dults. There is also limited information to inform decisions
bout frequency of risk assessment in persons who are
etermined to be at low or intermediate risk on initial risk
ssessment. High-risk persons are likely to initiate treat-
ent strategies, and repeat risk assessment is likely to be a
tandard component of patient follow-up. More research on
he optimal timing to begin risk assessment and repeat risk
ssessment in the asymptomatic patient is warranted.
.2. Other Test Strategies for Which
dditional Research Is Needed
.2.1. Magnetic Resonance Imaging
lthough MRI is an established cardiovascular imaging
odality, its use in risk assessment studies to date is very
imited. Research questions to be answered should focus on
) which MRI parameters are the best for predicting major
acro- and microvascular disease in the asymptomatic
atient, 2) whether such parameters add to existing risk
cores, and 3) what is the cost-effectiveness of such imaging
ccording to risk strata.
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t present the plethora of genetic tests available for assess-
ng cardiovascular risk has not reached the point of being
ble to add to the general risk assessment approach using
lobal risk scoring with traditional risk factors and addition
f careful family history. Additional research on the role of
enetic testing, with specific attention to the value for
ncremental risk prediction in asymptomatic people, is
eeded.
.2.3. Geographic and Environmental or
eighborhood Risks
uch research indicates that socioeconomic factors play
role in cardiovascular risk. It remains unclear how this
nformation should best be measured and incorporated
nto individual risk assessment or whether this area of
esearch applies primarily at the population and policy
evels. Attention to this area of research for individual
isk assessment was deemed to be warranted by the
riting committee.
.2.4. Role of Risk Assessment Strategies in
odifying Patient Outcomes
lthough the concept of individual risk assessment as a
eans of properly targeting intensity of risk treatments is
ow engrained in the practice of medicine and cardiol-
gy, data to support the clinical benefits of alternative
esting strategies are very limited. For example, would
isk assessments that use images of abnormal vessels be
ble to motivate patients and achieve better patient
utcomes than testing strategies that use only historical
nformation or blood tests? Studies that evaluate the
pecific testing strategy against a specific patient-centered
utcome are needed. In addition, comparative effective-
ess of various test strategies is needed to determine
osts, benefits, and comparative benefits of competing
esting approaches.
.3. Clinical Implications of Risk Assessment:
oncluding Comments
he assessment of risk for development of clinical manifes-
ations of atherosclerotic CVD is designed to aid the rlinician in informed decision making about lifestyle and
harmacologic interventions to reduce such risk. Patients
re broadly categorized into low-, intermediate-, and high-
isk subsets, and level of intensity and type of treatments are
ased on these differing assessments of risk.
The initial step in risk assessment in individual patients
nvolves the ascertainment of a global risk score (Framing-
am, Reynolds, etc.) and the elucidation of a family history
f atherosclerotic CVD. These Class I recommendations,
hich are simple and inexpensive, determine subsequent
trategies to be undertaken. Persons at low risk do not
equire further testing for risk assessment, as more intensive
nterventions are considered unwarranted, and those already
ocumented to be at high risk (established CHD or coro-
ary risk equivalents) are already candidates for intensive
reventive interventions, so that added testing will not
rovide incremental benefit.
For the intermediate-risk patient, this guideline should
elp the clinician select appropriate test modalities that can
urther define risk status. Tests classified as Class IIa are
hose shown to provide benefit that exceeds risk. Selection
mong these will vary with local availability and expertise,
ecisions regarding cost, and potential risks such as radia-
ion exposure, etc. Tests classified as Class IIb have less
obust evidence for benefit but may prove helpful in selected
atients. Tests classified as Class III are not recommended
or use in that there is no, or rather limited, evidence of their
enefit in incrementally adding to the assessment of risk;
herefore, these tests fail to contribute to changes in the
linical approach to therapy. In addition, a number of Class
II tests discussed in this guideline require additional efforts
o standardize the measurement or make the test more
ommonly available on a routine clinical basis. Furthermore,
ome of the Class III tests also pose potential harm
radiation exposure or psychological distress in the absence
f a defined treatment strategy) and are therefore to be
voided for cardiovascular risk assessment purposes in the
symptomatic adult. Until additional research is accom-
lished to justify the addition of Class III tests, the writing
ommittee recommends against their use for cardiovascular
isk assessment.
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ABI  ankle-brachial index
ApoB  apolipoprotein B
AUC  area under the curve
AV  atrioventricular
CAC  coronary artery calcium
CAD  coronary artery disease
CCTA  coronary computed tomography angiography
CHD  coronary heart disease
CRP  C-reactive protein
CT  computed tomography
CVD  cardiovascular disease
DTS  Duke treadmill score
ECG  electrocardiogram
FMD  flow-mediated dilation
FRS  Framingham risk score
HbA1C  hemoglobin A1C
HDL  high-density lipoprotein
hsCRP  high-sensitivity C-reactive protein
IMT  intima-media thickness
LDL  low-density lipoprotein
Lp(a)  lipoprotein(a)
Lp-PLA2  lipoprotein-associated phospholipase A2
LVH  left ventricular hypertrophy
MI  myocardial infarction
MPI  myocardial perfusion imaging
MRI  magnetic resonance imaging
PAD  peripheral artery disease
PAT  peripheral arterial tonometry
PET  positron emission tomography
PWV  pulse wave velocity
ROC  receiver operating characteristics
SNP  single nucleotide polymorphism
SPECT  single-photon emission computed tomography
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